



**AMENDMENTS TO THE CLAIMS**

1. (currently amended): A compound of Formula (I):




(I)


wherein Q is:



(IIa)



(IIb)



(IIc)

R<sup>1</sup> is selected from the group consisting of:

- (i) C<sub>1-8</sub> alkyl, and

C<sub>1-8</sub> alkyl substituted by substituent(s) independently selected from the group consisting of:

- oxo,
- halogen,
- C<sub>1-5</sub> alkoxy carbonyl,
- C<sub>1-5</sub> alkoxy,
- C<sub>1-5</sub> alkoxy substituted by carbocyclic aryl,
- mono-C<sub>1-5</sub> alkylamino,
- mono-C<sub>1-5</sub> alkylamino substituted by carbocyclic aryl,
- di-C<sub>1-5</sub> alkylamino,
- di-C<sub>1-5</sub> alkylamino substituted by carbocyclic aryl,

- C<sub>1-5</sub> alkylthio,
- C<sub>3-6</sub> cycloalkyl,
- C<sub>3-6</sub> cycloalkyl substituted by C<sub>1-5</sub> alkyl,
- C<sub>3-6</sub> cycloalkenyl,
- carbocyclyl,
- carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from the

group consisting of:

- hydroxy,
- halogen,
- nitro,
- amino,
- C<sub>1-5</sub> alkylcarbonylamino,
- C<sub>3-6</sub> cycloalkylcarbonylamino,
- carbocyclic aryl,
- C<sub>1-5</sub> alkyl,
- C<sub>1-5</sub> alkyl substituted by halogen,
- C<sub>1-5</sub> alkylsulfonyl,
- C<sub>2-6</sub> alkenyl,
- C<sub>1-5</sub> alkoxy, and
- C<sub>1-5</sub> alkoxy substituted by halogen,
- mono-carbocyclic arylamino,

•mono-carbocyclic arylamino substituted by substituent(s) independently

selected from the group consisting of:

- halogen,
- C<sub>1-5</sub> alkyl,
- C<sub>1-5</sub> alkyl substituted by halogen,
- C<sub>1-5</sub> alkoxy, and
- C<sub>1-5</sub> alkoxy substituted by halogen,

•di-carbocyclic arylamino,

•di-carbocyclic arylamino substituted by substituent(s) independently selected

from the group consisting of:

- halogen,
- C<sub>1-5</sub> alkyl,
- C<sub>1-5</sub> alkyl substituted by halogen,
- C<sub>1-5</sub> alkoxy, and
- C<sub>1-5</sub> alkoxy substituted by halogen,

•carbocyclic aryloxy,

•carbocyclic aryloxy substituted by substituent(s) independently selected from

the group consisting of:

- halogen,
- C<sub>1-5</sub> alkyl,
- C<sub>1-5</sub> alkyl substituted by halogen,
- C<sub>1-5</sub> alkoxy,
- C<sub>1-5</sub> alkoxy substituted by halogen, and

- carbocyclic aryl,
  - hydroxy,
  - heterocyclyl, and
  - heterocyclyl substituted by halogen,
- (ii) C<sub>2-5</sub> alkenyl, and
- C<sub>2-5</sub> alkenyl substituted by substituent(s) independently selected from the group consisting of:
- oxo, and
  - carbocyclic aryl,
- (iii) C<sub>2-5</sub> alkynyl,
- (iv) C<sub>3-12</sub> cycloalkyl, and
- C<sub>3-12</sub> cycloalkyl substituted by carbocyclic aryl,
- (v) carbocyclyl, and
- carbocyclyl substituted by substituent(s) independently selected from the group consisting of:
- hydroxy, and
  - carbocyclic aryl,
- (vi) carbocyclic aryl, and
- carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
- halogen,
  - cyano,
  - nitro,

- amino,

- C<sub>1-10</sub> alkyl,

- C<sub>1-10</sub> alkyl substituted by substituent(s) independently selected from the group

consisting of:

- halogen,

- oxo, and

- carbocyclic aryl,

- carboxy,

- C<sub>1-5</sub> alkoxy carbonyl,

- C<sub>1-7</sub> alkoxy,

- C<sub>1-7</sub> alkoxy substituted by substituent(s) independently selected from the

group consisting of:

- halogen, and

- carbocyclic aryl,

- C<sub>3-6</sub> cycloalkoxy,

- carbocyclic aryloxy,

- carbocyclic aryloxy substituted by substituent(s) independently selected from

the group consisting of:

- halogen,

- nitro,

- C<sub>1-5</sub> alkyl,

- C<sub>1-5</sub> alkyl substituted by halogen,

- C<sub>1-5</sub> alkoxy, and

- C<sub>1-5</sub> alkoxy substituted by halogen,
- heterocycloxy,
- heterocycloxy substituted by substituent(s) independently selected from the group consisting of:

- halogen,
- nitro,
- C<sub>1-5</sub> alkyl,
- C<sub>1-5</sub> alkyl substituted by halogen,
- C<sub>1-5</sub> alkoxy, and
- C<sub>1-5</sub> alkoxy substituted by halogen,
- mono-C<sub>1-5</sub> alkylamino,
- di-C<sub>1-5</sub> alkylamino,
- C<sub>1-5</sub> alkylcarbonylamino,
- C<sub>3-6</sub> cycloalkylcarbonylamino,
- C<sub>1-5</sub> alkoxy carbonylamino,
- carbocyclic aryl azo,
- carbocyclic aryl azo substituted by substituent(s) independently selected from the group consisting of:

- mono-C<sub>1-5</sub> alkylamino, and
- di-C<sub>1-5</sub> alkylamino,
- C<sub>1-5</sub> alkylthio,
- C<sub>1-5</sub> alkylthio substituted by halogen,
- carbocyclic arylthio,

- carbocyclic arylthio substituted by nitro,
- amino sulfonyl,
- heterocyclyl sulfonyl,
- C<sub>3-6</sub> cycloalkyl,
- C<sub>3-6</sub> cycloalkyl substituted by C<sub>1-5</sub> alkyl,
- carbocyclic aryl,
- carbocyclic aryl substituted by C<sub>1-5</sub> alkoxy,
- hydroxy,
- heterocyclyl, and
- heterocyclyl substituted by C<sub>1-5</sub> alkyl,

(vii) heterocyclyl, and

heterocyclyl substituted by substituent(s) independently selected from the

group consisting of:

- halogen,
- C<sub>1-5</sub> alkyl,
- C<sub>1-5</sub> alkyl substituted by halogen,
- C<sub>1-5</sub> alkoxy,
- C<sub>1-5</sub> alkoxy substituted by halogen,
- C<sub>1-5</sub> alkoxy carbonyl,
- C<sub>1-5</sub> alkoxy carbonyl substituted by carbocyclic aryl,
- carbocyclic aryloxy,

- carbocyclic aryloxy substituted by substituent(s) independently selected from

the group consisting of:

- halogen,
- nitro,
- cyano,
- hydroxy,
- C<sub>1-5</sub> alkyl,
- C<sub>1-5</sub> alkyl substituted by halogen,
- mono-C<sub>1-5</sub> alkylamino,
- di-C<sub>1-5</sub> alkylamino,
- C<sub>1-5</sub> alkylcarbonylamino,
- C<sub>3-6</sub> cycloalkylcarbonylamino,
- C<sub>1-5</sub> alkoxy,
- C<sub>1-5</sub> alkoxy substituted by halogen,
- C<sub>3-6</sub> cycloalkyl,
- C<sub>2-5</sub> alkenyl,
- C<sub>2-5</sub> alkynyl,
- carboxy,
- C<sub>1-5</sub> alkoxycarbonyl,
- mono-C<sub>1-5</sub> alkylaminocarbonyl,
- di-C<sub>1-5</sub> alkylaminocarbonyl,
- mono-C<sub>3-6</sub> cycloalkylaminocarbonyl,
- di-C<sub>3-6</sub> cycloalkylaminocarbonyl,
- mono-C<sub>1-5</sub> alkylaminocarbonylamino,
- di-C<sub>1-5</sub> alkylaminocarbonylamino,



Preliminary Amendment  
 U.S. National Stage Application of  
 PCT/JP2004/004554  
 -filed March 30, 2004

- mono-C<sub>3-6</sub> cycloalkylaminocarbonylamino,
- di-C<sub>3-6</sub> cycloalkylaminocarbonylamino,
- C<sub>1-5</sub> alkylthio,
- C<sub>1-5</sub> alkylthio substituted by halogen,
- C<sub>1-5</sub> alkylsulfinyl,
- C<sub>1-5</sub> alkylsulfinyl substituted by halogen,
- C<sub>1-5</sub> alkylsulfonyl, and
- C<sub>1-5</sub> alkylsulfonyl substituted by halogen,
- heterocycloxy,
- heterocycloxy substituted by substituent(s) independently selected from the

group consisting of:

- halogen,
- nitro,
- C<sub>1-5</sub> alkyl,
- C<sub>1-5</sub> alkyl substituted by halogen,
- C<sub>1-5</sub> alkoxy, and
- C<sub>1-5</sub> alkoxy substituted by halogen,
- carbocyclic aryl, and
- heterocyclyl;

R<sub>2</sub> is C<sub>1-5</sub> alkyl or -N(R<sub>2a</sub>)(R<sub>2b</sub>); wherein R<sub>2a</sub> and R<sub>2b</sub> are independently hydrogen or

C<sub>1-5</sub> alkyl;

R<sub>3</sub> is C<sub>1-5</sub> alkyl;

R<sub>4</sub> is -NHNH<sub>2</sub>, -NHNHBoc, -N(R<sub>4a</sub>)(R<sub>4b</sub>), morpholino, 4-acetyl-piperazyl, or 4-phenyl-piperazyl; wherein R<sub>4a</sub> is hydrogen or C<sub>1-5</sub> alkyl; R<sub>4b</sub> is C<sub>1-5</sub> alkyl, C<sub>1-5</sub> alkyl substituted by substituent(s) independently selected from the group consisting of:

- hydroxy,
- C<sub>1-5</sub> alkoxy,
- amino,
- NHBoc,
- C<sub>3-6</sub> cycloalkyl,
- carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from the

group consisting of:


- halogen,
- C<sub>1-5</sub> alkyl,
- C<sub>1-5</sub> alkoxy, and
- SO<sub>2</sub>NH<sub>2</sub>, and
- heterocyclyl,

C<sub>3-6</sub> cycloalkyl, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

- halogen,
- C<sub>1-5</sub> alkyl,
- C<sub>1-5</sub> alkoxy, and

a group of Formula (III):

Preliminary Amendment  
 U.S. National Stage Application of  
 PCT/JP2004/004554  
 -filed March 30, 2004








(III) ;

wherein Boc is carbamic acid *tert*-butyl ester and G is C<sub>1-5</sub> alkyl or C<sub>1-5</sub> alkyl substituted by substituent(s) independently selected from the group consisting of:

- carbocyclic aryl,
- halogenated carbocyclic aryl, and
- carbocyclic aryl substituted by C<sub>1-5</sub> alkoxy;

L is selected from the group consisting of Formulae (IV) to (XIX):





wherein  $R_5$  and  $R_6$  are independently hydrogen or  $C_{1-5}$  alkyl; and A and B are independently a single bond,  $-CH_2-$ , or  $-(CH_2)_2-$ ;

$X_1$ ,  $X_2$ ,  $X_3$  and  $X_4$  are independently selected from the group consisting of hydrogen, halogen,  $C_{1-4}$  alkyl,  $C_{1-4}$  alkyl substituted by halogen,  $C_{1-4}$  alkylthio,  $C_{1-4}$  alkylsulfinyl,  $C_{1-4}$  alkylsulfonyl,  $C_{1-4}$  alkoxy,  $C_{1-4}$  alkoxy substituted by halogen, nitro, amino, mono- $C_{1-4}$  alkylamino, di- $C_{1-4}$  alkylamino, piperidyl, morpholinyl, mono- $C_{1-4}$  alkylaminosulfonyl, di- $C_{1-4}$  alkylaminosulfonyl and hydroxy; provided that at least one substituent selected from the group consisting of  $X_1$ ,  $X_2$ ,  $X_3$  and  $X_4$  is not hydrogen; and

Y is selected from the group consisting of:

- (i)  $-C(O)NR_7-$ ,  $-C(S)NR_7-$ , or  $-C(O)O-$  when L is selected from the group consisting of Formulae (IV) to (XIX); wherein  $R_7$  is hydrogen or  $C_{1-5}$  alkyl;
- (ii)  $-S(O)_2-$ ,  $-C(O)-$ , a single bond or  $-CH_2-$  when L is selected from the group consisting of Formulae (IV) to (XI), and Q is Formula (IIa) or (IIb);
- (iii)  $-S(O)_2-$ ,  $-C(O)-$ , a single bond or  $-CH_2-$  when L is selected from the group consisting of Formulae (VII) to (XI), and Q is Formula (IIc); and
- (iv)  $-OC(O)-$  when L is selected from the group consisting of Formulae (XII) to (XIX);

Preliminary Amendment  
 U.S. National Stage Application of  
 PCT/JP2004/004554  
 -filed March 30, 2004

wherein carbocyclic aryl is phenyl, naphthyl, or biphenyl;

carbocyclyl is indanyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.1]heptenyl,  
~~adamantly~~ adamantyl, 9H-fluorenyl, menthyl, 1,2,3,4-tetrahydro-naphthalen-1-yl, or 1H-  
 indolyl;

heterocyclyl is 2,3-dihydro-benzo[1,4]dioxinyl, 3,4-dihydro-2H-  
 benzo[b][1,4]dioxepinyl, 4,5,6,7-tetrahydro-benzo[b]thienyl, 4H-benzo[1,3]dioxinyl,  
 benzo[1,3]dioxolyl, benzo[2,1,3]thiadiazolyl, benzothiazolyl, furyl, isoxazolyl, morpholinyl,  
 oxazolyl, piperidyl, pyrazolyl, pyridyl, tetrahydrofuryl, thienyl, dibenzofuranyl, 1H-  
 benzoimidazolyl, or thiazolyl; and

halogen is fluoro, chloro, bromo, or iodo;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

2. **(currently amended.):** The compound according to claim 1 wherein Q  
 is Formulae (IIa), (IIb), or (IIc);

R<sub>1</sub> is selected from the group consisting of:

(i) C<sub>1-8</sub> alkyl, and

C<sub>1-8</sub> alkyl substituted by substituent(s) independently selected from the group

consisting of:

- halogen,
- C<sub>1-5</sub> alkoxy carbonyl,
- C<sub>1-5</sub> alkoxy,
- C<sub>1-5</sub> alkoxy substituted by carbocyclic aryl,
- mono-C<sub>1-5</sub> alkylamino,
- di-C<sub>1-5</sub> alkylamino,

- C<sub>3-6</sub> cycloalkyl,
- C<sub>3-6</sub> cycloalkenyl,
- carbocyclyl,
- carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from the

group consisting of:

- hydroxy,
  - halogen,
  - nitro,
  - C<sub>1-5</sub> alkylcarbonylamino,
  - C<sub>3-6</sub> cycloalkylcarbonylamino,
  - C<sub>1-5</sub> alkyl,
  - C<sub>1-5</sub> alkyl substituted by halogen,
  - C<sub>1-5</sub> alkylsulfonyl,
  - C<sub>2-6</sub> alkenyl,
  - C<sub>1-5</sub> alkoxy,
  - C<sub>1-5</sub> alkoxy substituted by halogen, and
  - carbocyclic aryl,
  - heterocyclyl, and
  - heterocyclyl substituted by halogen,
- (ii) C<sub>2-5</sub> alkenyl, and
- C<sub>2-5</sub> alkenyl substituted by carbocyclic aryl,
- (iii) C<sub>2-5</sub> alkynyl,

- (iv) C<sub>3-12</sub> cycloalkyl, and  
C<sub>3-12</sub> cycloalkyl substituted by carbocyclic aryl,
- (v) carbocyclyl, and  
carbocyclyl by substituent(s) independently selected from the group consisting of:
  - hydroxy, and
  - carbocyclic aryl,
- (vi) carbocyclic aryl, and  
carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
  - halogen,
  - cyano,
  - nitro,
  - C<sub>1-10</sub> alkyl,
  - C<sub>1-10</sub> alkyl substituted by substituent(s) independently selected from the group consisting of:
    - halogen,
    - oxo, and
    - carbocyclic aryl,
  - carboxy,
  - C<sub>1-5</sub> alkoxy carbonyl,
  - C<sub>1-7</sub> alkoxy,

•C<sub>1-7</sub> alkoxy substituted by substituent(s) independently selected from the group consisting of:

- halogen, and
- carbocyclic aryl,
- carbocyclic aryloxy,
- carbocyclic aryloxy substituted by nitro,
- mono-C<sub>1-5</sub> alkylamino,
- di-C<sub>1-5</sub> alkylamino,
- C<sub>1-5</sub> alkoxy carbonylamino,
- carbocyclic aryl azo,
- carbocyclic aryl azo substituted by substituent(s) independently selected from the group consisting of:

- mono-C<sub>1-5</sub> alkylamino, and
- di-C<sub>1-5</sub> alkylamino,
- C<sub>1-5</sub> alkylthio,
- C<sub>1-5</sub> alkylthio substituted by halogen,
- carbocyclic arylthio,
- carbocyclic arylthio substituted by nitro,
- amino sulfonyl,
- heterocyclyl sulfonyl,
- C<sub>3-6</sub> cycloalkyl,
- C<sub>3-6</sub> cycloalkyl substituted by C<sub>1-5</sub> alkyl,
- carbocyclic aryl,



- heterocyclyl, and
  - heterocyclyl substituted by C<sub>1-5</sub> alkyl,
- (vii) heterocyclyl, and
- heterocyclyl substituted by substituent(s) independently selected from the group consisting of:

- halogen,
- C<sub>1-5</sub> alkyl,
- C<sub>1-5</sub> alkyl substituted by halogen,
- C<sub>1-5</sub> alkoxy,
- C<sub>1-5</sub> alkoxy carbonyl,
- C<sub>1-5</sub> alkoxy carbonyl substituted by carbocyclic aryl,
- carbocyclic aryloxy,
- carbocyclic aryl, and
- heterocyclyl;

R<sub>2</sub> is -N(R<sub>2a</sub>)(R<sub>2b</sub>), wherein R<sub>2a</sub> is hydrogen or C<sub>1-5</sub> alkyl; R<sub>2b</sub> is C<sub>1-5</sub> alkyl;

R<sub>3</sub> is C<sub>1-5</sub> alkyl;

R<sub>4</sub> is -N(R<sub>4a</sub>)(R<sub>4b</sub>) wherein R<sub>4a</sub> is hydrogen or C<sub>1-5</sub> alkyl; R<sub>4b</sub> is C<sub>1-5</sub> alkyl;

L is selected from Formula (V), (VIII), (IX), (XIII), (XVI), or (XVII);

X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub> and X<sub>4</sub> are independently selected from the group consisting of hydrogen, halogen, and C<sub>1-4</sub> alkyl; provided that at least one substituent selected from the group consisting of X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub> and X<sub>4</sub> is not hydrogen; and

Y is selected from the group consisting of:

(i) -C(O)NR<sub>7</sub>-, -C(S)NR<sub>7</sub>-, or -C(O)O- when L is selected from the group consisting of Formula (V), (VIII), (IX), (XIII), (XVI), or (XVII); wherein R<sub>7</sub> is hydrogen or C<sub>1-5</sub> alkyl;

(ii) -S(O)<sub>2</sub>-, -C(O)-, a single bond or -CH<sub>2</sub>- when L is selected from the group consisting of Formula (VIII) or (IX); and

(iii) -OC(O)- when L is selected from the group consisting of Formula (XIII), (XVI), or (XVII);

wherein carbocyclic aryl is phenyl or naphthyl;

carbocyclyl is indanyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.1]heptenyl, ~~adamantly~~adamantyl, 9H-fluorenyl, menthyl, 1,2,3,4-tetrahydro-naphthalen-1-yl, or 1H-indolyl;

heterocyclyl is 2,3-dihydro-benzo[1,4]dioxinyl, 3,4-dihydro-2H-benzo[b][1,4]dioxepinyl, 4,5,6,7-tetrahydro-benzo[b]thienyl, 4H-benzo[1,3]dioxinyl, benzo[1,3]dioxolyl, benzo[2,1,3]thiadiazolyl, benzothiazolyl, furyl, isoxazolyl, morpholinyl, oxazolyl, piperidyl, pyrazolyl, pyridyl, tetrahydrofuryl, thienyl, dibenzofuranyl, 1H-benzoimidazolyl, or thiazolyl; and

halogen is fluoro, chloro, bromo, or iodo;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

3. **(original):** The compound according to claim 2 wherein Q is Formula (IIc);

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

4. **(currently amended):** The compound according to claim 3 wherein R<sub>1</sub> is selected from the group consisting of:

- (i) C<sub>1-5</sub> alkyl, and
- C<sub>1-5</sub> alkyl substituted by substituent(s) independently selected from the group consisting of:
- C<sub>1-5</sub> alkoxy carbonyl,
  - carbocyclic aryl,
  - carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
- halogen,
  - C<sub>1-5</sub> alkyl,
  - C<sub>2-5</sub> alkenyl, and
  - C<sub>1-5</sub> alkoxy,
  - C<sub>1-5</sub> alkylthio, and
  - heterocyclyl,
- (ii) C<sub>3-6</sub> cycloalkyl, and
- C<sub>3-6</sub> cycloalkyl substituted by carbocyclic aryl,
- (iii) carbocyclyl,
- (iv) carbocyclic aryl, and
- carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
- halogen,
  - cyano,
  - nitro,
  - C<sub>1-5</sub> alkyl,

•C<sub>1-5</sub> alkyl substituted by substituent(s) independently selected from the group consisting of:

- halogen,
- oxo, and
- carbocyclic aryl,

•C<sub>1-5</sub> alkoxy carbonyl,

•C<sub>1-7</sub> alkoxy,

•C<sub>1-7</sub> alkoxy substituted by substituent(s) independently selected from the group consisting of:

- halogen, and
- carbocyclic aryl,

•cycloalkoxy,

•carbocyclic aryloxy,

•mono-C<sub>1-5</sub> alkylamino,

•di-C<sub>1-5</sub> alkylamino,

•C<sub>1-5</sub> alkylthio,

•C<sub>1-5</sub> alkylthio substituted by halogen,

•carbocyclic aryl,

•heterocyclyl, and

•heterocyclyl substituted by C<sub>1-5</sub> alkyl,

(v) heterocyclyl, and

heterocyclyl substituted by substituent(s) independently selected from the group consisting of:

- halogen,
- C<sub>1-5</sub> alkyl,
- C<sub>1-5</sub> alkyl substituted by halogen,
- C<sub>1-5</sub> alkoxy carbonyl
- C<sub>1-5</sub> alkoxy carbonyl substituted by carbocyclic aryl, and
- carbocyclic aryl;

L is Formula (V);

and

Y is -C(O)NR<sub>7</sub>-; wherein R<sub>7</sub> is hydrogen or C<sub>1-5</sub> alkyl;

wherein carbocyclic aryl is phenyl or naphthyl;

carbocyclyl is indanyl, ~~adamantyl~~ adamantyl, or 9H-fluorenyl;

heterocyclyl is 2,3-dihydro-benzo[1,4]dioxinyl, 3,4-dihydro-2H-benzo[b][1,4]dioxepinyl, 4H-benzo[1,3]dioxinyl, benzo[1,3]dioxolyl, benzothiazolyl, furyl, isoxazolyl, piperidyl, pyridyl, or thienyl; and

halogen is fluoro, chloro, bromo, or iodo;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

**5. (original):** The compound according to claim 4 wherein R<sub>4a</sub> is hydrogen or methyl; R<sub>4b</sub> is methyl; R<sub>5</sub> and R<sub>6</sub> are hydrogen; A is a single bond and B is a single bond or -CH<sub>2</sub>-; and R<sub>7</sub> is hydrogen;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

**6. (original):** The compound according to claim 5 wherein R<sub>1</sub> is selected from the group consisting of:

- (i) C<sub>1-5</sub> alkyl, and

C<sub>1-5</sub> alkyl substituted by substituent(s) independently selected from the group consisting of:

- C<sub>1-5</sub> alkoxy carbonyl,
- carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from the

group consisting of:

- halogen,
- C<sub>1-5</sub> alkyl,
- C<sub>2-5</sub> alkenyl, and
- C<sub>1-5</sub> alkoxy,

C<sub>1-5</sub> alkylthio, and

•heterocyclyl,

(ii) C<sub>3-6</sub> cycloalkyl, and

C<sub>3-6</sub> cycloalkyl substituted by carbocyclic aryl,

(iii) carbocyclyl,

(iv) carbocyclic aryl, and

carbocyclic aryl substituted by substituent(s) independently selected from the

group consisting of:

- halogen,
- cyano,
- nitro,
- C<sub>1-5</sub> alkyl,
- C<sub>1-5</sub> alkyl substituted by halogen,

- C<sub>1-5</sub> alkoxy carbonyl,
  - C<sub>1-5</sub> alkoxy,
  - C<sub>1-5</sub> alkoxy substituted by halogen,
  - cycloalkoxy,
  - carbocyclic aryloxy,
  - C<sub>1-5</sub> alkylthio, and
  - carbocyclic aryl,
- (v) heterocyclyl, and
- heterocyclyl substituted by substituent(s) independently selected from the group consisting of:

- halogen,
  - C<sub>1-5</sub> alkyl,
  - C<sub>1-5</sub> alkyl substituted by halogen, and
  - carbocyclic aryl;
- wherein carbocyclic aryl is phenyl or naphthyl;  
carbocyclyl is 9*H*-fluorenyl;  
heterocyclyl is 2,3-dihydro-benzo[1,4]dioxinyl, 3,4-dihydro-2*H*-benzo[b][1,4]dioxepinyl, 4*H*-benzo[1,3]dioxinyl, benzo[1,3]dioxolyl, furyl, isoxazolyl, or thienyl; and
- halogen is fluoro, chloro, bromo, or iodo;  
or a pharmaceutically acceptable salt, hydrate or solvate thereof.

7. **(original):** The compound according to claim 6 wherein R<sub>1</sub> is selected from the group consisting of:

- (i) C<sub>1-5</sub> alkyl, and  
C<sub>1-5</sub> alkyl substituted by substituent(s) independently selected from the group  
consisting of:
- C<sub>1-5</sub> alkoxy carbonyl,
  - carbocyclic aryl,
  - carbocyclic aryl substituted by substituent(s) independently selected from the  
group consisting of:
- halogen,
  - C<sub>1-5</sub> alkyl, and
  - C<sub>2-5</sub> alkenyl,
  - C<sub>1-5</sub> alkylthio,
- (ii) C<sub>3-6</sub> cycloalkyl, and  
C<sub>3-6</sub> cycloalkyl substituted by carbocyclic aryl,
- (iii) carbocyclic aryl, and  
carbocyclic aryl substituted by substituent(s) independently selected from the  
group consisting of:
- halogen,
  - cyano,
  - nitro,
  - C<sub>1-5</sub> alkyl,
  - C<sub>1-5</sub> alkyl substituted by halogen,
  - C<sub>1-5</sub> alkoxy carbonyl,
  - C<sub>1-5</sub> alkoxy,



- cycloalkoxy,
  - carbocyclic aryloxy,
  - C<sub>1-5</sub> alkylthio, and
  - carbocyclic aryl,
- (iv) heterocyclyl, and
- heterocyclyl substituted by substituent(s) independently selected from the group consisting of:

- C<sub>1-5</sub> alkyl,
- C<sub>1-5</sub> alkyl substituted by halogen, and
- carbocyclic aryl;

wherein carbocyclic aryl is phenyl or naphthyl;

heterocyclyl is 2,3-dihydro-benzo[1,4]dioxinyl, 3,4-dihydro-2*H*-benzo[b][1,4]dioxepinyl, benzo[1,3]dioxolyl, furyl, or isoxazolyl; and

halogen is fluoro, chloro, bromo, or iodo;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

**8. (original):** The compound according to claim 1 selected from the group consisting of:

N-benzyl-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;

N-(2-bromophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;

N-biphenyl-2-yl-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;

N-(4-bromophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;

N-butyl-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;

N-cyclohexyl-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;

N-(2-chlorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2,6-dimethylphenyl)urea;

N-(2,4-difluorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;

N-(2,4-dichlorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2,3-dimethylphenyl)urea;

ethyl 3-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)amino]carbonyl}amino)benzoate;

ethyl 4-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)amino]carbonyl}amino)benzoate;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-ethylphenyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-ethyl-6-methylphenyl)urea;

Preliminary Amendment  
 U.S. National Stage Application of  
 PCT/JP2004/004554  
 -filed March 30, 2004

ethyl N- {[ (cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl) amino] carbonyl} leucinate;

N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(4-fluorophenyl)urea;

N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-[1-(3-isopropenylphenyl)-1-methylethyl]urea;

methyl N- {[ (cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl) amino] carbonyl} methioninate;

N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(4-methoxyphenyl)urea;

N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(2-methoxyphenyl)urea;

N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(3-methoxyphenyl)urea;

N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-[4-(methylthio)-phenyl]urea;

N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(4-methoxybenzyl)urea;

N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-1-naphthylurea;

N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-[(2S)-2-phenylcyclopropyl]urea;

N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-phenylurea;

N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(4-  
phenoxyphenyl)urea;

N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-pentylurea;

N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-[2-  
(trifluoromethyl)phenyl]urea;

N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(4-  
methylphenyl)urea;

N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-mesitylurea;

N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(3-  
methylphenyl)urea;

N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(2-  
methylphenyl)urea;

N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-[1-(1-  
naphthyl)ethyl]urea;

methyl N- {[ (cis-4- {[4-(dimethylamino)quinazolin-2-  
yl]amino} cyclohexyl)amino]carbonyl} phenylalaninate;

N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(2,4,6-  
trichlorophenyl)urea;

N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(1-  
phenylethyl)urea;

1-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-3-(1-phenyl-ethyl)urea;

1-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-3-(1-naphthalen-1-yl-  
ethyl)urea;

N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-[2-(methylthio)-phenyl]urea;

N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(2,3,5,6-tetrachlorophenyl)urea;

N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(2,3-dimethyl-6-nitrophenyl)urea;

N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(2,4,6-tribromophenyl)urea;

N-(2,4-dibromo-6-fluorophenyl)-N'-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)urea;

N-(2,4-dibromophenyl)-N'-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)urea;

N-(2,4-dichlorobenzyl)-N'-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)urea;

N-(2,4-dimethoxyphenyl)-N'-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)urea;

N-(2,5-dimethoxyphenyl)-N'-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)urea;

N-(2,6-diethylphenyl)-N'-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)urea;

N-(2-chloro-5-nitrophenyl)-N'-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)urea;

N-[2-chloro-6-(trifluoromethyl)phenyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]-amino}cyclohexyl)urea;

N-(2-chloro-6-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)urea;

N-(2-chlorobenzyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-ethoxyphenyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-ethyl-6-isopropylphenyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-ethylphenyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-fluorobenzyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-iodophenyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-isopropyl-6-methylphenyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-isopropylphenyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-methoxy-4-nitrophenyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-methoxy-5-methylphenyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-methyl-3-nitrophenyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-methyl-4-nitrophenyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-methyl-5-nitrophenyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-methylbenzyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-nitrophenyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-propylphenyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-phenoxyphenyl)urea;

N-(2-tert-butyl-6-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;

N-(2-tert-butylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-[3-(methylthio)-phenyl]urea;

N-1,3-benzodioxol-5-yl-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(3,4,5-trimethoxyphenyl)urea;

N-(3,4-dichlorobenzyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;

N-(3,4-difluorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;

N-(3,4-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)urea;

N-(3,5-difluorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;

N-(3,5-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(3,5-dimethylphenyl)urea;

methyl 3-([(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)amino]carbonyl)amino)benzoate;

N-(3-chloro-2-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)urea;

N-(3-chloro-4-fluorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)urea;



N-(3-chloro-4-methoxyphenyl)-N'-(cis-4-{{4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;

N-(cis-4-{{4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(3-ethylphenyl)urea;

N-(cis-4-{{4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(3-fluorobenzyl)urea;

N-[4-bromo-2-(trifluoromethyl)phenyl]-N'-(cis-4-{{4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;

N-(4-bromo-2,6-difluorophenyl)-N'-(cis-4-{{4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;

N-(4-bromobenzyl)-N'-(cis-4-{{4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;

N-[4-chloro-2-(trifluoromethyl)phenyl]-N'-(cis-4-{{4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;

N-(4-chloro-2-methylphenyl)-N'-(cis-4-{{4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;

N-(4-cyanophenyl)-N'-(cis-4-{{4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;

N-(cis-4-{{4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-ethoxyphenyl)urea;

N-(cis-4-{{4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-fluoro-2-nitrophenyl)urea;

Preliminary Amendment  
 U.S. National Stage Application of  
 PCT/JP2004/004554  
 -filed March 30, 2004

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-fluorobenzyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-iodophenyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-methoxy-2-methylphenyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-methylbenzyl)urea;

N-(5-chloro-2,4-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(5-fluoro-2-methylphenyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-9H-fluoren-9-ylurea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-phenylethyl)urea;

N-cyclopentyl-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(diphenylmethyl)urea;

N-[1-(4-bromophenyl)ethyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;

N-(4-bromo-2,6-dimethylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;

N-(4-bromo-2-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)urea;

ethyl N-{[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)amino]carbonyl}phenylalaninate;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-[2-(2-thienyl)ethyl]urea;

N-(2,3-dihydro-1,4-benzodioxin-6-yl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;

N-(2,6-dibromo-4-isopropylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;

N-[3-(cyclopentyloxy)-4-methoxyphenyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;

N-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;

N-(4-butyl-2-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-[5-methyl-2-(trifluoromethyl)-3-furyl]urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(6-fluoro-4H-1,3-benzodioxin-8-yl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(3,5-dimethylisoxazol-4-yl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(3-methyl-5-phenylisoxazol-4-yl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(5-methyl-3-phenylisoxazol-4-yl)urea;

N-(2-bromophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;

N-biphenyl-2-yl-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;

N-butyl-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;

N-(3-chlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;

N-cyclohexyl-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;

N-(3-cyanophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;

N-(2-chlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2,6-dimethylphenyl)urea;

N-(3,4-dichlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;

N-(2,4-difluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;

N-(2,4-dichlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;

N-(3,5-dichlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;

N-(2,3-dichlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;

N-(2,6-difluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2,3-dimethylphenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(4-ethylphenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-ethyl-6-methylphenyl)urea;

ethyl N-([(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]amino)carbonyl)leucinate;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(4-fluorophenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-fluorophenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-fluorophenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[1-(3-isopropenylphenyl)-1-methylethyl]urea;

methyl N-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]amino}carbonyl)methioninate;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(4-methoxyphenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(4-methyl-2-nitrophenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-methoxyphenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-methoxyphenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[4-(methylthio)phenyl]urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-1-naphthylurea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-phenylurea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-pentylurea;

Preliminary Amendment  
 U.S. National Stage Application of  
 PCT/JP2004/004554  
 -filed March 30, 2004

N-[(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]-N'-[2-(trifluoromethyl)phenyl]urea;

N-[(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]-N'-(4-methylphenyl)urea;

N-[(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]-N'-mesitylurea;

N-[(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]-N'-(3-methylphenyl)urea;

N-[(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]-N'-(2-methylphenyl)urea;

N-[(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]-N'-(2,4,6-trichlorophenyl)urea;

N-[(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]-N'-(1-phenylethyl)urea;

1-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-3-(1-phenyl-ethyl)-urea;

1-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-3-(1-naphthalen-1-yl-ethyl)urea;

N-(2,6-diisopropylphenyl)-N'-[(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)methyl]urea;

N-[2-(difluoromethoxy)phenyl]-N'-[(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[2-(methylthio)phenyl]urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2,3,5,6-tetrachlorophenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2,3-dimethyl-6-nitrophenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2,4,6-tribromophenyl)urea;

N-(2,4-dibromo-6-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;

N-(2,4-dichlorobenzyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;

N-(2,5-dimethoxyphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;

N-(2,6-dibromo-4-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;

N-(2,6-dichlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;

N-(2,6-diethylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;

N-(2-chloro-5-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;



N-[2-chloro-6-(trifluoromethyl)phenyl]-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]-amino}cyclohexyl)methyl]urea;

N-(2-chloro-6-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)methyl]urea;

N-(2-chlorobenzyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-ethyl-6-isopropylphenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-ethylphenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-fluoro-5-nitrophenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-fluorobenzyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-iodophenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-isopropyl-6-methylphenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-isopropylphenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-methoxy-5-methylphenyl)urea;

N-[(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]-N'-(2-methoxy-5-nitrophenyl)urea;

N-[(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]-N'-(2-methyl-3-nitrophenyl)urea;

N-[(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]-N'-(2-methyl-4-nitrophenyl)urea;

N-[(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]-N'-(2-methyl-5-nitrophenyl)urea;

N-[(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]-N'-(2-methyl-6-nitrophenyl)urea;

N-[(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]-N'-(2-methylbenzyl)urea;

N-[(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]-N'-(2-nitrophenyl)urea;

N-[(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]-N'-(2-propylphenyl)urea;

N-[(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]-N'-(2-phenoxyphenyl)urea;

N-(2-tert-butyl-6-methylphenyl)-N'-[(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]urea;

N-(2-tert-butylphenyl)-N'-[(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[3-(methylthio)phenyl]urea;

N-(3,4-difluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;

N-(3,5-difluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;

N-(3,5-dimethoxyphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;

N-(3-chloro-2-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;

N-(3-chloro-4-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-ethylphenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[3-fluoro-5-(trifluoromethyl)phenyl]urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-fluorobenzyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(4,5-dimethyl-2-nitrophenyl)urea;

N-[4-bromo-2-(trifluoromethyl)phenyl]-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;

N-(4-bromo-2,6-difluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;

N-[4-chloro-2-(trifluoromethyl)phenyl]-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;

N-(4-chloro-2-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;

N-(4-cyanophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(4-fluoro-2-nitrophenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(4-fluorobenzyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(4-iodophenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(4-methoxy-2-methylphenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(4-methyl-3-nitrophenyl)urea;

N-(5-chloro-2-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(5-fluoro-2-methylphenyl)urea;

N-cyclopentyl-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(diphenylmethyl)urea;

N-(4-bromo-2,6-dimethylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;

N-(4-bromo-2-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;

N-(2,6-dibromo-4-isopropylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-3-thienylurea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[5-methyl-2-(trifluoromethyl)-3-furyl]urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(6-fluoro-4H-1,3-benzodioxin-8-yl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3,5-dimethylisoxazol-4-yl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-methyl-5-phenylisoxazol-4-yl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(5-methyl-3-phenylisoxazol-4-yl)urea; and

N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-[3-(trifluoromethoxy)phenyl]urea;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

**9. (original):** The compound according to claim 1 selected from the group consisting of:

N-(2-bromophenyl)-N'-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)urea;

N-biphenyl-2-yl-N'-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)urea;

N-butyl-N'-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)urea;

N-(2-chlorophenyl)-N'-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)urea;

N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(2,6-dimethylphenyl)urea;

N-(2,4-difluorophenyl)-N'-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)urea;

N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(2,3-dimethylphenyl)urea;

ethyl 3-([(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)amino]carbonyl)amino)benzoate;

N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(2-ethyl-6-methylphenyl)urea;

ethyl N- {[ (cis-4- {[ 4-(dimethylamino)quinazolin-2-yl] amino} cyclohexyl) amino]-  
carbonyl} leucinate;

N-(cis-4- {[ 4-(dimethylamino)quinazolin-2-yl] amino} cyclohexyl)-N'-(4-  
fluorophenyl)urea;

N-(cis-4- {[ 4-(dimethylamino)quinazolin-2-yl] amino} cyclohexyl)-N'-[1-(3-  
isopropenylphenyl)-1-methylethyl]urea;

methyl N- {[ (cis-4- {[ 4-(dimethylamino)quinazolin-2-yl] amino} cyclohexyl) amino]-  
carbonyl} methioninate;

N-(cis-4- {[ 4-(dimethylamino)quinazolin-2-yl] amino} cyclohexyl)-N'-(4-  
(methylthio)phenyl)urea;

N-(cis-4- {[ 4-(dimethylamino)quinazolin-2-yl] amino} cyclohexyl)-N'-1-naphthylurea;

N-(cis-4- {[ 4-(dimethylamino)quinazolin-2-yl] amino} cyclohexyl)-N'-[(2S)-2-  
phenylcyclopropyl]urea;

N-(cis-4- {[ 4-(dimethylamino)quinazolin-2-yl] amino} cyclohexyl)-N'-(4-  
phenoxyphenyl)urea;

N-(cis-4- {[ 4-(dimethylamino)quinazolin-2-yl] amino} cyclohexyl)-N'-pentylurea;

N-(cis-4- {[ 4-(dimethylamino)quinazolin-2-yl] amino} cyclohexyl)-N'-[2-  
(trifluoromethyl)phenyl]urea;

N-(cis-4- {[ 4-(dimethylamino)quinazolin-2-yl] amino} cyclohexyl)-N'-mesitylurea;

N-(cis-4- {[ 4-(dimethylamino)quinazolin-2-yl] amino} cyclohexyl)-N'-(2-  
methylphenyl)urea;

N-(cis-4- {[ 4-(dimethylamino)quinazolin-2-yl] amino} cyclohexyl)-N'-[1-(1-  
naphthyl)ethyl]urea;

methyl N- {[ (cis-4- {[ 4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)amino]carbonyl}phenylalaninate;

N-(cis-4- {[ 4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(2,4,6-trichlorophenyl)urea;

N-(cis-4- {[ 4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(1-phenylethyl)urea;

1-[4-(4-Dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-3-(1-phenyl-ethyl)urea;

N-(cis-4- {[ 4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(2,3,5,6-tetrachlorophenyl)urea;

N-(cis-4- {[ 4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(2,4,6-tribromophenyl)urea;

N-(2,4-dibromo-6-fluorophenyl)-N'-(cis-4- {[ 4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)urea;

N-(2,4-dibromophenyl)-N'-(cis-4- {[ 4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)urea;

N-(2,4-dichlorobenzyl)-N'-(cis-4- {[ 4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)urea;

N-(2,4-dimethoxyphenyl)-N'-(cis-4- {[ 4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)urea;

N-(2,6-diethylphenyl)-N'-(cis-4- {[ 4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)urea;

N-[2-chloro-6-(trifluoromethyl)phenyl]-N'-(cis-4- {[ 4-(dimethylamino)quinazolin-2-yl]-amino} cyclohexyl)urea;



N-(2-chloro-6-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)urea;

N-(2-chlorobenzyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(2-ethoxyphenyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(2-ethyl-6-isopropylphenyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(2-ethylphenyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(2-fluorobenzyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(2-iodophenyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(2-isopropyl-6-methylphenyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(2-isopropylphenyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(2-methyl-3-nitrophenyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(2-methyl-4-nitrophenyl)urea;

N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(2-methyl-5-nitrophenyl)urea;

N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(2-methylbenzyl)urea;

N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(2-nitrophenyl)urea;

N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(2-propylphenyl)urea;

N-(2-tert-butyl-6-methylphenyl)-N'-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)urea;

N-(2-tert-butylphenyl)-N'-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)urea;

N-1,3-benzodioxol-5-yl-N'-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)urea;

N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(3,4,5-trimethoxyphenyl)urea;

N-(3,4-dimethoxyphenyl)-N'-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)urea;

N-(3-chloro-2-methylphenyl)-N'-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)urea;

N-(3-chloro-4-methoxyphenyl)-N'-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)urea;

N-[4-bromo-2-(trifluoromethyl)phenyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]-amino}cyclohexyl)urea;

N-(4-bromo-2,6-difluorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;

N-(4-bromobenzyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;

N-[4-chloro-2-(trifluoromethyl)phenyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]-amino}cyclohexyl)urea;

N-(4-chloro-2-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)urea;

N-(4-cyanophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-fluorobenzyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-methoxy-2-methylphenyl)urea;

N-(5-chloro-2,4-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(diphenylmethyl)urea;

N-[1-(4-bromophenyl)ethyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)urea;

N-(4-bromo-2,6-dimethylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;

N-(4-bromo-2-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)urea;

ethyl N- {[ (cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)amino]carbonyl}phenylalaninate;

N-(2,3-dihydro-1,4-benzodioxin-6-yl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;

N-(2,6-dibromo-4-isopropylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;

N-[3-(cyclopentyloxy)-4-methoxyphenyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;

N-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;

N-(4-butyl-2-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-[5-methyl-2-(trifluoromethyl)-3-furyl]urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(3-methyl-5-phenylisoxazol-4-yl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(5-methyl-3-phenylisoxazol-4-yl)urea;

N-(2-chlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2,6-dimethylphenyl)urea;

N-(2,4-difluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;

N-(3,5-dichlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;

N-(2,3-dichlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2,3-dimethylphenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-ethyl-6-methylphenyl)urea;

ethyl N-([(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]amino)carbonyl)leucinate;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(4-fluorophenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[4-(methylthio)phenyl]urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-phenylurea;

Preliminary Amendment  
 U.S. National Stage Application of  
 PCT/JP2004/004554  
 -filed March 30, 2004

N-[(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]-N'-[2-(trifluoromethyl)phenyl]urea;

N-[(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]-N'-(4-methylphenyl)urea;

N-[(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]-N'-mesitylurea;

N-[(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]-N'-(2-methylphenyl)urea;

N-[(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]-N'-(2,4,6-trichlorophenyl)urea;

N-(2,6-diisopropylphenyl)-N'-[(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]urea;

N-[(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]-N'-(2,3-dimethyl-6-nitrophenyl)urea;

N-[(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]-N'-(2,4,6-tribromophenyl)urea;

N-(2,4-dibromo-6-fluorophenyl)-N'-[(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]urea;

N-(2,6-dibromo-4-fluorophenyl)-N'-[(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]urea;

N-(2,6-dichlorophenyl)-N'-[(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]urea;

Preliminary Amendment  
U.S. National Stage Application of  
PCT/JP2004/004554  
-filed March 30, 2004

N-(2,6-diethylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;

N-[2-chloro-6-(trifluoromethyl)phenyl]-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]-amino}cyclohexyl)methyl]urea;

N-(2-chloro-6-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)methyl]urea;

N-(2-chlorobenzyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-ethyl-6-isopropylphenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-ethylphenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-iodophenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-isopropyl-6-methylphenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-isopropylphenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-methoxy-5-methylphenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-methyl-3-nitrophenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-methyl-6-nitrophenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-propylphenyl)urea;

N-(2-tert-butyl-6-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;

N-(2-tert-butylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;

N-(3,4-difluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;

N-(3,5-difluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;

N-(3-chloro-2-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)methyl]urea;

N-(3-chloro-4-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)methyl]urea;

N-(4-bromo-2,6-difluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;

N-[4-chloro-2-(trifluoromethyl)phenyl]-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]-amino}cyclohexyl)methyl]urea;

N-(4-cyanophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;



N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(diphenylmethyl)urea;

N-(4-bromo-2,6-dimethylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[5-methyl-2-(trifluoromethyl)-3-furyl]urea; and

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-methyl-5-phenylisoxazol-4-yl)urea;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

**10. (currently amended):** The compound according to claim 3 wherein R<sub>1</sub> is selected from the group consisting of:

(i) C<sub>1-8</sub> alkyl, and

C<sub>1-8</sub> alkyl substituted by substituent(s) independently selected from the group consisting of:

•mono-C<sub>1-5</sub> alkylamino,

•di-C<sub>1-5</sub> alkylamino,

•C<sub>3-6</sub> cycloalkyl,

•C<sub>3-6</sub> cycloalkenyl,

•carbocyclic aryl,

•carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••C<sub>1-5</sub> alkyl, and

- C<sub>1-5</sub> alkoxy,
- heterocyclyl,
- (ii) C<sub>2-5</sub> alkynyl,
- (iii) C<sub>2-5</sub> alkenyl, and  
C<sub>2-5</sub> alkenyl substituted by carbocyclic aryl,
- (iv) C<sub>3-12</sub> cycloalkyl,
- (v) carbocyclyl,
- (vi) carbocyclic aryl, and  
carbocyclic aryl substituted by substituent(s) independently selected from the  
group consisting of:
  - halogen,
  - cyano,
  - nitro,
  - C<sub>1-10</sub> alkyl,
  - C<sub>1-10</sub> alkyl substituted by substituent(s) independently selected from the group  
consisting of:
    - halogen, and
    - oxo,
    - carboxy,
    - C<sub>1-5</sub> alkoxy carbonyl,
    - C<sub>1-5</sub> alkoxy,
    - C<sub>1-5</sub> alkoxy substituted by substituent(s) independently selected from the  
group consisting of:

Preliminary Amendment  
 U.S. National Stage Application of  
 PCT/JP2004/004554  
 -filed March 30, 2004

- halogen, and
- carbocyclic aryl,

- carbocyclic aryloxy,
- carbocyclic aryloxy substituted by nitro,
- mono-C<sub>1-5</sub> alkylamino,
- di-C<sub>1-5</sub> alkylamino,
- C<sub>1-5</sub> alkoxy carbonylamino,
- carbocyclic aryl azo,
- carbocyclic aryl azo substituted by substituent(s) independently selected from

the group consisting of:

- mono-C<sub>1-5</sub> alkylamino, and
  - di-C<sub>1-5</sub> alkylamino,
  - C<sub>1-5</sub> alkylthio,
  - C<sub>1-5</sub> alkylthio substituted by halogen,
  - carbocyclic arylthio,
  - carbocyclic arylthio substituted by nitro,
  - amino sulfonyl,
  - heterocyclyl sulfonyl,
  - C<sub>3-6</sub> cycloalkyl,
  - C<sub>3-6</sub> cycloalkyl substituted by C<sub>1-5</sub> alkyl,
  - carbocyclic aryl, and
  - heterocyclyl,
- (vii) heterocyclyl, and

heterocyclyl substituted by substituent(s) independently selected from the group consisting of:

- C<sub>1-5</sub> alkyl,
- C<sub>1-5</sub> alkoxy carbonyl,
- carbocyclic aryloxy,
- carbocyclic aryl, and
- heterocyclyl;

L is Formula (V); and

Y is -C(S)NR<sub>7</sub>-; wherein R<sub>7</sub> is hydrogen or C<sub>1-5</sub> alkyl;

wherein carbocyclic aryl is phenyl or naphthyl;

carbocyclyl is indanyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.1]heptenyl, or ~~adamantly~~adamantyl;

heterocyclyl is 2,3-dihydro-benzo[1,4]dioxinyl, 4,5,6,7-tetrahydro-benzo[b]thienyl, benzo[1,3]dioxolyl, benzo[2,1,3]thiadiazolyl, furyl, isoxazolyl, morpholinyl, oxazolyl, piperidyl, pyrazolyl, pyridyl, tetrahydrofuryl, or thienyl; and

halogen is fluoro, chloro, bromo, or iodo;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

**11. (original):** The compound according to claim 10 wherein R<sub>4a</sub> is hydrogen or methyl; R<sub>4b</sub> is methyl; R<sub>5</sub> and R<sub>6</sub> are hydrogen; A is a single bond; B is a single bond or -CH<sub>2</sub>-; and R<sub>7</sub> is hydrogen;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

**12. (original):** The compound according to claim 11 wherein R<sub>1</sub> is selected from the group consisting of:

- (i) C<sub>1-6</sub> alkyl, and
- C<sub>1-6</sub> alkyl substituted by substituent(s) independently selected from the group consisting of:
- C<sub>3-6</sub> cycloalkyl,
  - C<sub>3-6</sub> cycloalkenyl,
  - carbocyclic aryl,
  - carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
- halogen,
  - C<sub>1-5</sub> alkyl, and
  - C<sub>1-5</sub> alkoxy,
  - heterocyclyl,
- (ii) C<sub>3-12</sub> cycloalkyl,
- (iii) carbocyclyl,
- (iv) carbocyclic aryl, and
- carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
- halogen,
  - cyano,
  - nitro,
  - C<sub>1-5</sub> alkyl,
  - C<sub>1-5</sub> alkyl substituted by halogen,
  - C<sub>1-5</sub> alkoxy carbonyl,

- C<sub>1-5</sub> alkoxy,
  - C<sub>1-5</sub> alkoxy substituted by halogen,
  - mono-C<sub>1-5</sub> alkylamino,
  - di-C<sub>1-5</sub> alkylamino,
  - C<sub>1-5</sub> alkylthio, and
  - carbocyclic aryl,
- (v) heterocyclyl, and
- heterocyclyl substituted by substituent(s) independently selected from the group consisting of:

- C<sub>1-5</sub> alkyl,
- C<sub>1-5</sub> alkoxy carbonyl, and
- carbocyclic aryl;

wherein carbocyclic aryl is phenyl or naphthyl;

carbocyclyl is indanyl, bicyclo[2.2.1]heptyl, or bicyclo[2.2.1]heptenyl;

heterocyclyl is 2,3-dihydro-benzo[1,4]dioxinyl, benzo[1,3]dioxolyl, isoxazolyl, tetrahydrofuryl, or thienyl; and

halogen is fluoro, chloro, bromo, or iodo;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

13. **(original):** The compound according to claim 12 wherein R<sub>1</sub> is selected from the group consisting of:

- (i) C<sub>1-5</sub> alkyl, and

C<sub>1-5</sub> alkyl substituted by substituent(s) independently selected from the group consisting of:

- carbocyclic aryl,

- carbocyclic aryl substituted by substituent(s) independently selected from the

group consisting of:

- halogen, and

- C<sub>1-5</sub> alkoxy,

(ii) carbocyclyl,

(iii) carbocyclic aryl, and

carbocyclic aryl substituted by substituent(s) independently selected from the

group consisting of:

- halogen,

- cyano,

- nitro,

- C<sub>1-5</sub> alkyl,

- C<sub>1-5</sub> alkyl substituted by halogen,

- C<sub>1-5</sub> alkoxy carbonyl,

- C<sub>1-5</sub> alkoxy,

- C<sub>1-5</sub> alkoxy substituted by halogen,

- mono-C<sub>1-5</sub> alkylamino,

- di-C<sub>1-5</sub> alkylamino, and

- carbocyclic aryl,

(iv) heterocyclyl, and

heterocyclyl substituted by substituent(s) independently selected from the

group consisting of:

- C<sub>1-5</sub> alkyl,
- C<sub>1-5</sub> alkoxy carbonyl, and

•carbocyclic aryl;

wherein carbocyclic aryl is phenyl or naphthyl;

carbocyclyl is bicyclo[2.2.1]heptyl;

heterocyclyl is 2,3-dihydro-benzo[1,4]dioxinyl, benzo[1,3]dioxolyl,

isoxazolyl, or thienyl; and

halogen is fluoro, chloro, bromo, or iodo;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

**14. (original):** The compound according to claim 1 selected from the group consisting of:

N-(4-bromophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;

N-(4-cyanophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;

N-cyclohexyl-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;

N-cyclopentyl-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;

N-(4-chlorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-thiourea;

N-(2,4-dichlorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;



Preliminary Amendment  
 U.S. National Stage Application of  
 PCT/JP2004/004554  
 -filed March 30, 2004

N-(2,4-dimethoxyphenyl)-N'-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-  
 cyclohexyl)thiourea;

N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(2,6-  
 dimethylphenyl)thiourea;

N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(2-ethyl-6-  
 isopropylphenyl)thiourea;

N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(4-  
 fluorophenyl)thiourea;

N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-hexylthiourea;

N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-isobutylthiourea;

N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(4-  
 methoxybiphenyl-3-yl)thiourea;

N-(1,3-benzodioxol-5-ylmethyl)-N'-(cis-4- {[4-(dimethylamino)quinazolin-2-  
 yl]amino} cyclohexyl)thiourea;

N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-[4-  
 (methylthio)phenyl]thiourea;

N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(4-  
 methoxyphenyl)thiourea;

N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(2-  
 methoxyphenyl)thiourea;

N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-1-  
 naphthylthiourea;

Preliminary Amendment  
U.S. National Stage Application of  
PCT/JP2004/004554  
-filed March 30, 2004

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-nitrophenyl)-thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(pentafluorophenyl)thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-propylthiourea;  
N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(3,4,5-trimethoxyphenyl)thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-methylphenyl)thiourea;

N-(3,4-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-ethylphenyl)-thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-[2-(methylthio)phenyl]thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-[2-(trifluoromethoxy)phenyl]thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2,3,4-trifluorophenyl)thiourea;

N-(2,5-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;

N-(2-chloro-4-nitrophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;

N-(cis-4-{{4-(dimethylamino)quinazolin-2-yl}amino}cyclohexyl)-N'-(2-ethylphenyl)-thiourea;

N-(cis-4-{{4-(dimethylamino)quinazolin-2-yl}amino}cyclohexyl)-N'-(2-iodophenyl)-thiourea;

N-(cis-4-{{4-(dimethylamino)quinazolin-2-yl}amino}cyclohexyl)-N'-(2-methoxy-4-nitrophenyl)thiourea;

N-(cis-4-{{4-(dimethylamino)quinazolin-2-yl}amino}cyclohexyl)-N'-(2-methoxy-5-methylphenyl)thiourea;

N-(cis-4-{{4-(dimethylamino)quinazolin-2-yl}amino}cyclohexyl)-N'-(3-iodophenyl)-thiourea;

N-(cis-4-{{4-(dimethylamino)quinazolin-2-yl}amino}cyclohexyl)-N'-(3-methoxyphenyl)thiourea;

N-[4-(difluoromethoxy)phenyl]-N'-(cis-4-{{4-(dimethylamino)quinazolin-2-yl}amino}cyclohexyl)thiourea;

N-(cis-4-{{4-(dimethylamino)quinazolin-2-yl}amino}cyclohexyl)-N'-[4-(trifluoromethyl)phenyl]thiourea;

N-(4-bromo-2-chlorophenyl)-N'-(cis-4-{{4-(dimethylamino)quinazolin-2-yl}amino}-cyclohexyl)thiourea;

N-(cis-4-{{4-(dimethylamino)quinazolin-2-yl}amino}cyclohexyl)-N'-(4-iodophenyl)-thiourea;

N-(5-chloro-2-methylphenyl)-N'-(cis-4-{{4-(dimethylamino)quinazolin-2-yl}amino}-cyclohexyl)thiourea;

N-[(1S,4R)-bicyclo[2.2.1]hept-2-yl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;

N-[2-(4-chlorophenyl)ethyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2,4,6-tribromophenyl)thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2,4,6-trichlorophenyl)thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-mesitylthiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2,4-dimethylphenyl)thiourea;

N-(2,6-diethylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;

N-(2,6-diisopropylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)thiourea;

N-(2-bromo-4-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)thiourea;

N-(2-chlorobenzyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-ethyl-6-methylphenyl)thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-isopropylphenyl)thiourea;

Preliminary Amendment  
U.S. National Stage Application of  
PCT/JP2004/004554  
-filed March 30, 2004

N-(3,5-dimethoxyphenyl)-N'-(cis-4-{{4-(dimethylamino)quinazolin-2-yl}amino}-  
cyclohexyl)thiourea;

N-(cis-4-{{4-(dimethylamino)quinazolin-2-yl}amino} cyclohexyl)-N'-(3,5-  
dimethylphenyl)thiourea;

N-(3-chloro-4-methylphenyl)-N'-(cis-4-{{4-(dimethylamino)quinazolin-2-yl}amino}-  
cyclohexyl)thiourea;

methyl 3-(((cis-4-{{4-(dimethylamino)quinazolin-2-yl}amino} cyclohexyl)amino]-  
carbonothioyl) amino)benzoate;

N-(4-bromo-2,6-dimethylphenyl)-N'-(cis-4-{{4-(dimethylamino)quinazolin-2-  
yl}amino} cyclohexyl)thiourea;

N-(4-bromo-2-methylphenyl)-N'-(cis-4-{{4-(dimethylamino)quinazolin-2-yl}amino}-  
cyclohexyl)thiourea;

N-[4-bromo-2-(trifluoromethyl)phenyl]-N'-(cis-4-{{4-(dimethylamino)quinazolin-2-  
yl}amino} cyclohexyl)thiourea;

N-(4-chloro-2-methylphenyl)-N'-(cis-4-{{4-(dimethylamino)quinazolin-2-yl}amino}-  
cyclohexyl)thiourea;

N-(cis-4-{{4-(dimethylamino)quinazolin-2-yl}amino} cyclohexyl)-N'-[1-(4-  
fluorophenyl)ethyl]thiourea;

N-(cis-4-{{4-(dimethylamino)quinazolin-2-yl}amino} cyclohexyl)-N'-(4-  
fluorobenzyl)thiourea;

N-(cis-4-{{4-(dimethylamino)quinazolin-2-yl}amino} cyclohexyl)-N'-(4-  
isopropylphenyl)thiourea;

N-(cis-4-{{4-(dimethylamino)quinazolin-2-yl}amino}cyclohexyl)-N'-(4-methoxybenzyl)thiourea;

methyl 4-({[(cis-4-{{4-(dimethylamino)quinazolin-2-yl}amino}cyclohexyl)amino]-carbonothioyl}amino)benzoate;

N-(cis-4-{{4-(dimethylamino)quinazolin-2-yl}amino}cyclohexyl)-N'-(1-phenylethyl)-thiourea;

N-(cis-4-{{4-(dimethylamino)quinazolin-2-yl}amino}cyclohexyl)-N'-(diphenylmethyl)thiourea;

N-(cyclohexylmethyl)-N'-(cis-4-{{4-(dimethylamino)quinazolin-2-yl}amino}cyclohexyl)thiourea;

N-cyclooctyl-N'-(cis-4-{{4-(dimethylamino)quinazolin-2-yl}amino}cyclohexyl)thiourea;

N-cyclopropyl-N'-(cis-4-{{4-(dimethylamino)quinazolin-2-yl}amino}cyclohexyl)thiourea;

N-(cis-4-{{4-(dimethylamino)quinazolin-2-yl}amino}cyclohexyl)-N'-(1-naphthylmethyl)thiourea;

N-(cis-4-{{4-(dimethylamino)quinazolin-2-yl}amino}cyclohexyl)-N'-(2,2-diphenylethyl)thiourea;

N-(2,3-dimethoxybenzyl)-N'-(cis-4-{{4-(dimethylamino)quinazolin-2-yl}amino}cyclohexyl)thiourea;

N-(cis-4-{{4-(dimethylamino)quinazolin-2-yl}amino}cyclohexyl)-N'-(2,4,5-trimethylphenyl)thiourea;

Preliminary Amendment  
U.S. National Stage Application of  
PCT/JP2004/004554  
-filed March 30, 2004

N-[2-(2,5-dimethoxyphenyl)ethyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;

N-biphenyl-2-yl-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-fluorobenzyl)thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-methyl-4-nitrophenyl)thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-methylbenzyl)thiourea;

N-(3-chlorobenzyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;

ethyl 3-([(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)amino]-carbonothioyl)amino)benzoate;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(3-ethylphenyl)thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(3-fluorobenzyl)thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(3-methoxybenzyl)thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(3-methylbenzyl)thiourea;

N-[4-chloro-2-(trifluoromethyl)phenyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-fluoro-2-methylphenyl)thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-methoxy-2-methylphenyl)thiourea;

N-(5-chloro-2,4-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;

N-(2,3-dihydro-1H-inden-5-yl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;

N-cycloheptyl-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-[(1R)-1-phenylethyl]thiourea;

N-(2-cyclohex-1-en-1-ylethyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2,3-dimethylphenyl)thiourea;

N-(2,4-dibromo-6-fluorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;

N-(2,4-dichloro-6-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;



N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(2,5-dimethylphenyl)thiourea;

N-(2-bromo-4-isopropylphenyl)-N'-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)thiourea;

N-(2-bromo-5-fluorophenyl)-N'-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)thiourea;

N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(2-ethoxyphenyl)thiourea;

N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(2-isopropyl-6-methylphenyl)thiourea;

N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(2-methoxybenzyl)thiourea;

N-(2,3-dihydro-1,4-benzodioxin-6-yl)-N'-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)thiourea;

N-1,3-benzodioxol-5-yl-N'-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)thiourea;

N-(3-chloro-2-methylphenyl)-N'-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)thiourea;

N-[4-bromo-2-(trifluoromethoxy)phenyl]-N'-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)thiourea;

N-(4-chloro-2,5-dimethoxyphenyl)-N'-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-phenylbutyl)-thiourea;

N-bicyclo[2.2.1]hept-2-yl-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)thiourea;

methyl 3-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)amino]-carbonothioyl}amino)-4-methylthiophene-2-carboxylate;

methyl 3-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)amino]-carbonothioyl}amino)thiophene-2-carboxylate;

N-(2-bromo-4-fluorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)thiourea;

N-(4-butyl-2-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)thiourea;

N-[4-(dimethylamino)-1-naphthyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(5-methyl-3-phenylisoxazol-4-yl)thiourea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2,6-dimethylphenyl)thiourea;

N-(2,6-dichlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-ethyl-6-isopropylphenyl)thiourea;

N-[(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]-N'-isobutylthiourea;

N-(1,3-benzodioxol-5-yl)methyl)-N'-[(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]thiourea;

N-[(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]-N'-(4-nitrophenyl)thiourea;

N-[(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]-N'-(pentafluorophenyl)thiourea;

N-[(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]-N'-(tetrahydrofuran-2-yl)methyl)thiourea;

N-[(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]-N'-[2-(trifluoromethoxy)phenyl]thiourea;

N-[(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]-N'-(2,3,4-trifluorophenyl)thiourea;

N-[(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]-N'-(2-ethylphenyl)thiourea;

N-(5-chloro-2-methylphenyl)-N'-[(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]thiourea;

N-[(1S,4R)-bicyclo[2.2.1]hept-2-yl]-N'-[(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]thiourea;

N-[2-(3,4-dimethoxyphenyl)ethyl]-N'-[(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]thiourea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2,4,6-tribromophenyl)thiourea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2,4,6-trichlorophenyl)thiourea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-mesitylthiourea;

N-(2,6-diethylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea;

N-(2,6-diisopropylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-ethyl-6-methylphenyl)thiourea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-isopropylphenyl)thiourea;

N-(4-bromo-2,6-dimethylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea;

N-[4-bromo-2-(trifluoromethyl)phenyl]-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[1-(4-fluorophenyl)ethyl]thiourea;

N-(5-chloro-2-methoxyphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]-N'-(diphenylmethyl)thiourea;

N-cyclododecyl-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]thiourea;

N-(cyclohexylmethyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]thiourea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]-N'-(2,3,5,6-tetrachlorophenyl)thiourea;

N-(2,3-dimethoxybenzyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]thiourea;

N-(2,4-dichlorobenzyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]thiourea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]-N'-(2-methoxy-5-nitrophenyl)thiourea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]-N'-(4-methoxy-2-methylphenyl)thiourea;

N-(2,4-dibromo-6-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]thiourea;

N-(2,4-dichloro-6-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]thiourea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]-N'-(2,5-dimethylphenyl)thiourea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-ethoxyphenyl)thiourea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-isopropyl-6-methylphenyl)thiourea;

N-[4-bromo-2-(trifluoromethoxy)phenyl]-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea;

N-bicyclo[2.2.1]hept-2-yl-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea;

N-bicyclo[2.2.1]hept-5-en-2-yl-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea;

N-(cyclopropylmethyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea; and

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(5-methyl-3-phenylisoxazol-4-yl)thiourea;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

**15. (original):** The compound according to claim 1 selected from the group consisting of:

N-(4-bromophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;

N-(4-cyanophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;

N-(2,4-dichlorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;

N-(2,4-dimethoxyphenyl)-N'-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-  
cyclohexyl)thiourea;

N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(2,6-  
dimethylphenyl)thiourea;

N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(2-ethyl-6-  
isopropylphenyl)thiourea;

N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(2-  
methoxyphenyl)thiourea;

N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-1-  
naphthylthiourea;

N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(3,4,5-  
trimethoxyphenyl)thiourea;

N-(3,4-dimethoxyphenyl)-N'-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-  
cyclohexyl)thiourea;

N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(2-ethylphenyl)-  
thiourea;

N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(2-methoxy-4-  
nitrophenyl)thiourea;

N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(2-methoxy-5-  
methylphenyl)thiourea;

N-(4-bromo-2-chlorophenyl)-N'-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-  
cyclohexyl)thiourea;

N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(4-iodophenyl)-thiourea;

N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(2,4,6-tribromophenyl)thiourea;

N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(2,4,6-trichlorophenyl)thiourea;

N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-mesitylthiourea;

N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(2,4-dimethylphenyl)thiourea;

N-(2,6-diethylphenyl)-N'-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)thiourea;

N-(2-bromo-4-methylphenyl)-N'-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)thiourea;

N-(2-chlorobenzyl)-N'-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)thiourea;

N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(2-ethyl-6-methylphenyl)thiourea;

N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(2-isopropylphenyl)thiourea;

methyl 3-([[(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)amino]-carbonothioyl] amino)benzoate;

N-(4-bromo-2,6-dimethylphenyl)-N'-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)thiourea;



N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(4-fluoro-2-methylphenyl)thiourea;

N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(4-methoxy-2-methylphenyl)thiourea;

N-(5-chloro-2,4-dimethoxyphenyl)-N'-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)thiourea;

N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-[(1R)-1-phenylethyl]thiourea;

N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(2,3-dimethylphenyl)thiourea;

N-(2,4-dibromo-6-fluorophenyl)-N'-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)thiourea;

N-(2,4-dichloro-6-methylphenyl)-N'-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)thiourea;

N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(2-ethoxyphenyl)thiourea;

N-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(2-isopropyl-6-methylphenyl)thiourea;

N-(2,3-dihydro-1,4-benzodioxin-6-yl)-N'-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)thiourea;

N-1,3-benzodioxol-5-yl-N'-(cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)thiourea;

Preliminary Amendment  
U.S. National Stage Application of  
PCT/JP2004/004554  
-filed March 30, 2004

N-(cis-4-{{4-(dimethylamino)quinazolin-2-yl}amino}cyclohexyl)-N'-(4-fluoro-2-methylphenyl)thiourea;

N-(cis-4-{{4-(dimethylamino)quinazolin-2-yl}amino}cyclohexyl)-N'-(4-methoxy-2-methylphenyl)thiourea;

N-(5-chloro-2,4-dimethoxyphenyl)-N'-(cis-4-{{4-(dimethylamino)quinazolin-2-yl}amino}cyclohexyl)thiourea;

N-(cis-4-{{4-(dimethylamino)quinazolin-2-yl}amino}cyclohexyl)-N'-[(1R)-1-phenylethyl]thiourea;

N-(cis-4-{{4-(dimethylamino)quinazolin-2-yl}amino}cyclohexyl)-N'-(2,3-dimethylphenyl)thiourea;

N-(2,4-dibromo-6-fluorophenyl)-N'-(cis-4-{{4-(dimethylamino)quinazolin-2-yl}amino}cyclohexyl)thiourea;

N-(2,4-dichloro-6-methylphenyl)-N'-(cis-4-{{4-(dimethylamino)quinazolin-2-yl}amino}cyclohexyl)thiourea;

N-(cis-4-{{4-(dimethylamino)quinazolin-2-yl}amino}cyclohexyl)-N'-(2-ethoxyphenyl)thiourea;

N-(cis-4-{{4-(dimethylamino)quinazolin-2-yl}amino}cyclohexyl)-N'-(2-isopropyl-6-methylphenyl)thiourea;

N-(2,3-dihydro-1,4-benzodioxin-6-yl)-N'-(cis-4-{{4-(dimethylamino)quinazolin-2-yl}amino}cyclohexyl)thiourea;

N-1,3-benzodioxol-5-yl-N'-(cis-4-{{4-(dimethylamino)quinazolin-2-yl}amino}cyclohexyl)thiourea;

N-(3-chloro-2-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)thiourea;

N-[4-bromo-2-(trifluoromethoxy)phenyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;

N-(4-chloro-2,5-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;

N-bicyclo[2.2.1]hept-2-yl-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)thiourea;

methyl 3-([(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)amino]-carbonothioyl)amino)-4-methylthiophene-2-carboxylate;

methyl 3-([(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)amino]-carbonothioyl)amino)thiophene-2-carboxylate;

N-(4-butyl-2-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)thiourea;

N-[4-(dimethylamino)-1-naphthyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(5-methyl-3-phenylisoxazol-4-yl)thiourea;

N-(2,6-diethylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea;

N-(4-bromo-2,6-dimethylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]-N'-(2,3,5,6-tetrachlorophenyl)thiourea; and

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]-N'-(2-isopropyl-6-methylphenyl)thiourea;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

**16. (currently amended):** The compound according to claim 3 wherein:

~~R1 is selected from the group consisting of:~~

R<sub>1</sub> is selected from the group consisting of:

(i) C<sub>1-8</sub> alkyl, and

C<sub>1-8</sub> alkyl substituted by substituent(s) independently selected from the group consisting of:

- halogen,
- C<sub>1-5</sub> alkoxy,
- C<sub>1-5</sub> alkoxy substituted by carbocyclic aryl,
- carbocyclyl,
- carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from the

group consisting of:

- halogen,
- nitro, and
- C<sub>1-5</sub> alkoxy,

(ii) C<sub>2-5</sub> alkenyl,

(iii) carbocyclyl,

(iv) carbocyclic aryl, and  
carbocyclic aryl substituted by substituent(s) independently selected from the  
group consisting of:

- halogen,
- C<sub>1-5</sub> alkyl,
- C<sub>1-5</sub> alkyl substituted by halogen, and
- C<sub>1-5</sub> alkoxy;

L is Formula (V); and

Y is -C(O)O-;

wherein carbocyclic aryl is phenyl or naphthyl;

carbocyclyl is 9*H*-fluorenyl or menthyl; and

halogen is fluoro, chloro, bromo, or iodo;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

17. **(original):** The compound according to claim 16 wherein R<sub>4a</sub> is hydrogen or methyl; R<sub>4b</sub> is methyl; R<sub>5</sub> and R<sub>6</sub> are hydrogen; A is a single bond; and B is a single bond or -CH<sub>2</sub>-;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

18. **(original):** The compound according to claim 1 selected from the group consisting of:

cis-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-carbamic acid 2-benzyloxy-ethyl ester;

cis-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-carbamic acid 4,5-dimethoxy-2-nitro-benzyl ester;

cis-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-carbamic acid 2-chloro-benzyl ester;

cis-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-carbamic acid 4,5-dimethoxy-2-nitro-benzyl ester;

cis-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-carbamic acid 4-nitro-benzyl ester;

cis-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-carbamic acid benzyl ester;

cis-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-carbamic acid 2-chloro-benzyl ester;

cis-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-carbamic acid 4-nitro-benzyl ester; and

cis-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-carbamic acid benzyl ester;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

**19. (original):** The compound according to claim 3 wherein:

R<sub>1</sub> is C<sub>1-8</sub> alkyl, and

C<sub>1-8</sub> alkyl substituted by substituent(s) independently selected from the group consisting of:

•carbocyclic aryl,

•carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

••halogen,

- C<sub>1-5</sub> alkyl,
- C<sub>1-5</sub> alkyl substituted by halogen,
- C<sub>1-5</sub> alkoxy, and
- C<sub>1-5</sub> alkoxy substituted by halogen,

R<sub>4</sub> is -N(R<sub>4a</sub>)(R<sub>4b</sub>) wherein R<sub>4a</sub> and R<sub>4b</sub> are independently C<sub>1-5</sub> alkyl;

L is Formula (VIII) or (IX) wherein R<sub>5</sub> and R<sub>6</sub> are both hydrogen; A and B are each independently a single bond or -CH<sub>2</sub>-; and

Y is a single bond;

wherein carbocyclic aryl is phenyl; and

halogen is fluoro or chloro;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

20. **(original):** The compound according to claim 19 wherein:

R<sub>1</sub> is C<sub>1-8</sub> alkyl, and

C<sub>1-8</sub> alkyl substituted by substituent(s) independently selected from the group consisting of:

- carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from the

group consisting of:

- C<sub>1-5</sub> alkoxy, and
- C<sub>1-5</sub> alkoxy substituted by halogen,

wherein carbocyclic aryl is phenyl; and

halogen is fluoro or chloro;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

**21. (original):** The compound according to claim 20 wherein:

R<sub>4</sub> is -N(CH<sub>3</sub>)<sub>2</sub>; L is Formula (VIII) or (IX) wherein A is a single bond and B is -CH<sub>2</sub>-, or A is -CH<sub>2</sub>- and B is a single bond; and Y is a single bond;

wherein carbocyclic aryl is phenyl; and

halogen is fluoro;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

**22. (original):** The compound according to claim 1 is:

N2-[(1S,3R)-3-({[4-bromo-2-(trifluoromethoxy)benzyl]amino}-methyl)cyclopentyl]-N4,N4-dimethylquinazoline-2,4-diamine;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

**23. (original):** The compound according to claim 3 wherein:

R<sub>1</sub> is selected from the group consisting of:

(i) C<sub>1-8</sub> alkyl, and

C<sub>1-8</sub> alkyl substituted by substituent(s) independently selected from the group consisting of:

•carbocyclic aryl,

•carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

••hydroxy,

••halogen,

••nitro,

••C<sub>1-5</sub> alkylcarbonylamino,

••C<sub>3-6</sub> cycloalkylcarbonylamino,



- C<sub>1-5</sub> alkyl,
- C<sub>1-5</sub> alkyl substituted by halogen,
- C<sub>1-5</sub> alkylsulfonyl,
- C<sub>1-5</sub> alkoxy,
- C<sub>1-5</sub> alkoxy substituted by halogen, and
- carbocyclic aryl,
- heterocyclyl, and
- heterocyclyl substituted by halogen,
- (ii) C<sub>3-12</sub> cycloalkyl, and  
C<sub>3-12</sub> cycloalkyl substituted by carbocyclic aryl,
- (iii) carbocyclyl, and  
carbocyclyl by substituent(s) independently selected from the group consisting  
of:
  - hydroxy, and
  - carbocyclic aryl,
- (iv) carbocyclic aryl, and  
carbocyclic aryl substituted by substituent(s) independently selected from the  
group consisting of:
  - halogen,
  - C<sub>1-5</sub> alkoxy, and
  - nitro,
- (v) heterocyclyl, and

heterocyclyl substituted by substituent(s) independently selected from the group consisting of:

- halogen, and

- C<sub>1-5</sub> alkoxy,

R<sub>4</sub> is -N(R<sub>4a</sub>)(R<sub>4b</sub>) wherein R<sub>4a</sub> and R<sub>4b</sub> are each independently C<sub>1-5</sub> alkyl;

L is Formula (XIII); wherein R<sub>5</sub> and R<sub>6</sub> are both hydrogen; A is a single bond and B is a single bond or -CH<sub>2</sub>-; and

Y is -C(O)NR<sub>7</sub>-, wherein R<sub>7</sub> is hydrogen or C<sub>1-5</sub> alkyl;

wherein carbocyclic aryl is phenyl or naphthyl;

carbocyclyl is indanyl, 9*H*-fluorenyl, 1,2,3,4-tetrahydro-naphthalen-1-yl, or 1*H*-indolyl;

heterocyclyl is benzo[1,3]dioxolyl, pyridyl, dibenzofuranyl, 1*H*-benzoimidazolyl, or thiazolyl; and

halogen is fluoro, chloro, bromo, or iodo;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

**24. (original):** The compound according to claim 23 wherein:

R<sub>1</sub> is selected from the group consisting of:

- (i) C<sub>1-8</sub> alkyl, and

C<sub>1-8</sub> alkyl substituted by substituent(s) independently selected from the group consisting of:

- carbocyclic aryl,

- carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

- hydroxy,
  - halogen,
  - nitro,
  - C<sub>1-5</sub> alkylcarbonylamino,
  - C<sub>1-5</sub> alkyl,
  - C<sub>1-5</sub> alkyl substituted by halogen,
  - C<sub>1-5</sub> alkylsulfonyl,
  - C<sub>1-5</sub> alkoxy,
  - C<sub>1-5</sub> alkoxy substituted by halogen, and
  - carbocyclic aryl,
  - heterocyclyl, and
  - heterocyclyl substituted by halogen,
- (ii) C<sub>3-12</sub> cycloalkyl, and  
C<sub>3-12</sub> cycloalkyl substituted by carbocyclic aryl,
- (iii) carbocyclyl,
- (iv) carbocyclic aryl, and  
carbocyclic aryl substituted by substituent(s) independently selected from the  
group consisting of:
- halogen, and
  - nitro,
- (v) heterocyclyl, and  
heterocyclyl substituted by substituent(s) independently selected from the  
group consisting of:

Preliminary Amendment  
 U.S. National Stage Application of  
 PCT/JP2004/004554  
 -filed March 30, 2004

•halogen, and

•C<sub>1-5</sub> alkoxy,

wherein carbocyclic aryl is phenyl or naphthyl;

carbocyclyl is indanyl, 9*H*-fluorenyl, or 1,2,3,4-tetrahydro-naphthalen-1-yl;

heterocyclyl is benzo[1,3]dioxolyl, or pyridyl;

and

halogen is fluoro, chloro, bromo, or iodo;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

**25. (original):** The compound according to claim 24 wherein R<sub>4</sub> is -N(CH<sub>3</sub>)<sub>2</sub>;

A and B are both a single bond; and Y is -C(O)NH-;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

**26. (original):** The compound according to claim 1 selected from the group consisting of:

cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} -N-(2,3-dimethylbenzyl)-

cyclohexanecarboxamide;

cis-N-(2-bromobenzyl)-4- {[4-(dimethylamino)quinazolin-2-yl]amino} -

cyclohexanecarboxamide;

cis-N-(2-chlorobenzyl)-4- {[4-(dimethylamino)quinazolin-2-yl]amino} -

cyclohexanecarboxamide;

cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino} -N-(4-methylbenzyl)-

cyclohexanecarboxamide;

cis-N-[3,5-bis(trifluoromethyl)benzyl]-4- {[4-(dimethylamino)quinazolin-2-

yl]amino} cyclohexanecarboxamide;

cis-N-(2,4-dimethoxybenzyl)-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-  
cyclohexanecarboxamide;

cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-N-(1,2,3,4-tetrahydronaphthalen-1-  
yl)cyclohexanecarboxamide;

cis-N-(2,3-dihydro-1H-inden-2-yl)-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-  
cyclohexanecarboxamide;

cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-N-[(1S)-1-(4-nitrophenyl)ethyl]-  
cyclohexanecarboxamide;

cis-N-(3,5-dichlorobenzyl)-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-  
cyclohexanecarboxamide;

cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-N-[4-(trifluoromethoxy)benzyl]-  
cyclohexanecarboxamide;

cis-N-(4-bromobenzyl)-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-  
cyclohexanecarboxamide;

cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-N-(4-methoxybenzyl)-  
cyclohexanecarboxamide;

cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-N-(2-fluoro-4-nitrophenyl)-  
cyclohexanecarboxamide;

cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-N-(3-fluoro-4-methylbenzyl)-  
cyclohexanecarboxamide;

cis-N-(5-chloro-2-methylbenzyl)-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-  
cyclohexanecarboxamide; and

cis-N-(2,4-dichloro-6-methylbenzyl)-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-  
cyclohexanecarboxamide;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

**27. (original):** The compound according to claim 1 selected from the group  
consisting of:

cis-N-(2,3-dimethoxybenzyl)-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-  
cyclohexanecarboxamide;

cis-N-(2,4-difluorobenzyl)-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-  
cyclohexanecarboxamide;

cis-N-(2,4-dichlorobenzyl)-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-  
cyclohexanecarboxamide;

cis-N-(2,3-dichlorobenzyl)-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-  
cyclohexanecarboxamide;

cis-N-(2,5-dichlorobenzyl)-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-  
cyclohexanecarboxamide;

cis-N-(3-chlorobenzyl)-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-  
cyclohexanecarboxamide;

cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-N-(3-methoxybenzyl)-  
cyclohexanecarboxamide;

cis-N-(3,4-dimethoxybenzyl)-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-  
cyclohexanecarboxamide;

cis-N-(3,5-dimethoxybenzyl)-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-  
cyclohexanecarboxamide;

cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-N-(4-hydroxy-3-methoxybenzyl)-  
cyclohexanecarboxamide;

cis-N-(1,3-benzodioxol-5-ylmethyl)-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-  
cyclohexanecarboxamide;

cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-N-[(1R)-1-(4-nitrophenyl)ethyl]-  
cyclohexanecarboxamide;

cis-4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexanecarboxylic acid (trans- 2-  
phenylcyclopropyl)amide;

cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-N-[(1S)-1-(4-methylphenyl)ethyl]-  
cyclohexanecarboxamide;

cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-N-[(1R)-1-(1-naphthyl)ethyl]-  
cyclohexanecarboxamide;

cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-N-[3-(trifluoromethyl)benzyl]-  
cyclohexanecarboxamide;

cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-N-(3-methoxyphenyl)-  
cyclohexanecarboxamide;

cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-N-(3-iodobenzyl)-  
cyclohexanecarboxamide;

cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-N-(4-methoxybenzyl)-  
cyclohexanecarboxamide;

cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-N-(3-iodophenyl)-  
cyclohexanecarboxamide;

cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-N-[3-(propionylamino)benzyl]-  
cyclohexanecarboxamide;

cis-N-benzyl-4- {[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexanecarboxamide;

cis-N-[(6-chloropyridin-3-yl)methyl]-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-  
cyclohexanecarboxamide;

cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-N-[(1R)-1-(3-  
methoxyphenyl)ethyl]cyclohexanecarboxamide;

cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-N-[1-(4-fluorophenyl)ethyl]-  
cyclohexanecarboxamide;

cis-N-[(1R)-1-(4-chlorophenyl)ethyl]-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-  
cyclohexanecarboxamide;

cis-N-[1-(4-bromophenyl)ethyl]-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-  
cyclohexanecarboxamide;

cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-N-[(1S)-1-(1-naphthyl)ethyl]-  
cyclohexanecarboxamide;

cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-N-(3,5-dimethylbenzyl)-  
cyclohexanecarboxamide;

cis-N-(3-chloro-2-methylbenzyl)-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-  
cyclohexanecarboxamide;

cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-N-(5-fluoro-2-methylbenzyl)-  
cyclohexanecarboxamide;

cis-N-(3-chloro-2,6-difluorobenzyl)-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-  
cyclohexanecarboxamide;



cis-N-(biphenyl-3-ylmethyl)-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-  
cyclohexanecarboxamide;

cis-N-(biphenyl-4-ylmethyl)-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-  
cyclohexanecarboxamide;

cis-N-(6-chloro-2-fluoro-3-methylbenzyl)-4- {[4-(dimethylamino)quinazolin-2-  
yl]amino}cyclohexanecarboxamide;

cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-N-(2-fluorobenzyl)-  
cyclohexanecarboxamide;

cis-N-(2,6-difluorobenzyl)-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-  
cyclohexanecarboxamide;

cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-N-[4-(trifluoromethyl)benzyl]-  
cyclohexanecarboxamide;

cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-N-(1-naphthylmethyl)-  
cyclohexanecarboxamide;

cis-N-(4-chlorobenzyl)-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-  
cyclohexanecarboxamide;

cis-N-(3,4-dichlorobenzyl)-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-  
cyclohexanecarboxamide;

cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-N-(3-fluorobenzyl)-  
cyclohexanecarboxamide;

cis-N-(2,5-difluorobenzyl)-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-  
cyclohexanecarboxamide;

cis-N-(2,3-difluorobenzyl)-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-  
cyclohexanecarboxamide;

cis-N-(3-bromobenzyl)-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-  
cyclohexanecarboxamide;

cis-N-(3-bromo-4-fluorobenzyl)-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-  
cyclohexanecarboxamide;

cis-N-(4-bromo-2-fluorobenzyl)-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-  
cyclohexanecarboxamide;

cis-N-(5-bromo-2-fluorobenzyl)-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-  
cyclohexanecarboxamide;

cis-N-(4-chloro-2-fluorobenzyl)-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-  
cyclohexanecarboxamide;

cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-N-(3-methylbenzyl)-  
cyclohexanecarboxamide;

cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-N-(2-methylbenzyl)-  
cyclohexanecarboxamide;

cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-N-[2-(trifluoromethoxy)benzyl]-  
cyclohexanecarboxamide;

cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-N-(2,3,4-trifluorobenzyl)-  
cyclohexanecarboxamide;

cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-N-(2,4,5-trifluorobenzyl)-  
cyclohexanecarboxamide;

cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-N-(3,4,5-trifluorobenzyl)-  
cyclohexanecarboxamide;

cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-N-(2,3,6-trifluorobenzyl)-  
cyclohexanecarboxamide;

cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-N-[3-fluoro-5-  
(trifluoromethyl)benzyl]cyclohexanecarboxamide;

cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-N-[4-fluoro-2-  
(trifluoromethyl)benzyl]cyclohexanecarboxamide;

cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-N-[2-fluoro-4-  
(trifluoromethyl)benzyl]cyclohexanecarboxamide;

cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-N-[4-fluoro-3-  
(trifluoromethyl)benzyl]cyclohexanecarboxamide;

cis-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-N-[2-fluoro-3-  
(trifluoromethyl)benzyl]cyclohexanecarboxamide;

cis-N-[4-chloro-3-(trifluoromethyl)benzyl]-4- {[4-(dimethylamino)quinazolin-2-  
yl]amino}cyclohexanecarboxamide;

cis-N-(2-chloro-6-fluorobenzyl)-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-  
cyclohexanecarboxamide;

cis-N-(3-chloro-4-fluorobenzyl)-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-  
cyclohexanecarboxamide;

cis-N-(2-chloro-4-fluorobenzyl)-4- {[4-(dimethylamino)quinazolin-2-yl]amino}-  
cyclohexanecarboxamide;

cis-N-[2-chloro-5-(trifluoromethyl)benzyl]-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexanecarboxamide;

cis-N-[2-(difluoromethoxy)benzyl]-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexanecarboxamide;

cis-N-[3-(difluoromethoxy)benzyl]-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexanecarboxamide;

cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[3-(trifluoromethoxy)benzyl]-cyclohexanecarboxamide;

cis-N-(2,6-dimethoxybenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexanecarboxamide;

cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[(1R)-1-phenylethyl]-cyclohexanecarboxamide;

cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[(1S)-1-(4-methoxyphenyl)ethyl]cyclohexanecarboxamide;

cis-N-[bis(4-methoxyphenyl)methyl]-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexanecarboxamide;

cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[2-(trifluoromethyl)benzyl]-cyclohexanecarboxamide;

cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-9H-fluoren-9-ylcyclohexanecarboxamide;

cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[4-(methylsulfonyl)benzyl]-cyclohexanecarboxamide; and

cis-N-(6-chloropyridin-3-yl)-4-[[4-(dimethylamino)quinazolin-2-yl]amino]-  
cyclohexanecarboxamide;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

**28. (original):** The compound according to claim 3 wherein:

R<sub>1</sub> is selected from the group consisting of:

(i) C<sub>1-8</sub> alkyl, and

C<sub>1-8</sub> alkyl substituted by substituent(s) independently selected from the group consisting of:

•carbocyclic aryl,

•carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

••C<sub>1-5</sub> alkoxy, and

••C<sub>1-5</sub> alkoxy substituted by halogen,

(ii) carbocyclic aryl, and

carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

•halogen, and

•C<sub>1-7</sub> alkoxy,

R<sub>4</sub> is -N(R<sub>4a</sub>)(R<sub>4b</sub>) wherein R<sub>4a</sub> and R<sub>4b</sub> are each independently C<sub>1-5</sub> alkyl;

L is Formula (XIII) wherein R<sub>5</sub> is hydrogen; A is a single bond and B is a single bond or -CH<sub>2</sub>-; and

Y is -C(O)O- or -OC(O)-;

wherein carbocyclic aryl is phenyl or naphthyl; and

halogen is fluoro, chloro, bromo, or iodo;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

**29. (original):** The compound according to claim 28 wherein  $R_4$  is  $-N(CH_3)_2$ ;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

**30. (original):** The compound according to claim 3 wherein:

$R_1$  is selected from the group consisting of:

carbocyclic aryl, and

carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

- halogen,

- $C_{1-10}$  alkyl,

- $C_{1-10}$  alkyl substituted by halogen,

- $C_{1-7}$  alkoxy, and

- $C_{1-7}$  alkoxy substituted by halogen,

$R_4$  is  $-N(R_{4a})(R_{4b})$  wherein  $R_{4a}$  and  $R_{4b}$  are each independently  $C_{1-5}$  alkyl;

L is Formula (VIII) or (IX) wherein A and B are each independently a single bond or

$-CH_2-$ ; and

Y is  $-C(O)-$ ,

wherein carbocyclic aryl is phenyl; and

halogen is fluoro, chloro, bromo, or iodo;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

**31. (original):** The compound according to claim 30 wherein  $R_4$  is  $-N(CH_3)_2$ ;  $R_5$  and  $R_6$  are both hydrogen; and A is a single bond, and B is  $-CH_2-$ ; or A is a  $-CH_2-$ , and B is a single bond,

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

**32. (original):** The compound according to claim 1 selected from the group consisting of:

3,4-dichloro-N-(((1R,3S)-3-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclopentyl)methyl]benzamide;

N-[(1S,3R)-3-([4-(dimethylamino)quinazolin-2-yl]amino)methyl]cyclopentyl]-4-fluorobenzamide;

4-chloro-N-(((1R,3S)-3-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclopentyl)methyl]benzamide; and

N-(((1R,3S)-3-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclopentyl)methyl)-3,5-difluorobenzamide;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

**33. (original):** The compound according to claim 1 selected from the group consisting of:

N-(((1R,3S)-3-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclopentyl)methyl)-3,5-dimethoxybenzamide;

2,4,6-trichloro-N-(((1R,3S)-3-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclopentyl)methyl]benzamide;

N-(((1R,3S)-3-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclopentyl)methyl)-3-fluoro-4-(trifluoromethyl)benzamide;

N-(((1R,3S)-3-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclopentyl)methyl)-4-(trifluoromethoxy)benzamide; and

N-[(1S,3R)-3-({[4-(dimethylamino)quinazolin-2-yl]amino}methyl)cyclopentyl]-2,4-difluorobenzamide;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

**34. (original):** The compound according to claim 2 wherein Q is Formula (IIa).

**35. (original):** The compound according to claim 34 wherein:

R<sub>1</sub> is selected from the group consisting of:

- (i) C<sub>1-8</sub> alkyl, and  
C<sub>1-8</sub> alkyl substituted by carbocyclic aryl,
- (ii) carbocyclic aryl, and  
carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

- halogen,
- C<sub>1-10</sub> alkyl,
- C<sub>1-10</sub> alkyl substituted by halogen,
- C<sub>1-7</sub> alkoxy, and
- C<sub>1-7</sub> alkoxy substituted by halogen,

R<sub>2</sub> is -N(R<sub>2a</sub>)(R<sub>2b</sub>), wherein R<sub>2a</sub> and R<sub>2b</sub> are each independently C<sub>1-5</sub> alkyl;

L is Formula (V) wherein R<sub>5</sub> and R<sub>6</sub> are both hydrogen; A and B are both a single bond;



X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub> and X<sub>4</sub> are independently selected from the group consisting of hydrogen, halogen, and C<sub>1-4</sub> alkyl; provided that at least one substituent selected from the group consisting of X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub> and X<sub>4</sub> is not hydrogen; and

Y is -C(O)-;

wherein carbocyclic aryl is phenyl; and

halogen is fluoro, chloro, bromo, or iodo;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

**36. (original):** The compound according to claim 35 wherein R<sub>2</sub> is -N(CH<sub>3</sub>)<sub>2</sub>; and X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub> and X<sub>4</sub> are independently selected from the group consisting of hydrogen, fluoro, and methyl; provided that at least one substituent selected from the group consisting of X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub> and X<sub>4</sub> is not hydrogen;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

**37. (original):** The compound according to claim 1 selected from the group consisting of:

N-(cis-4-{[4-(dimethylamino)-6-methylquinazolin-2-yl]amino}cyclohexyl)-2,2-diphenylacetamide;

N-(cis-4-{[4-(dimethylamino)-6-methylquinazolin-2-yl]amino}cyclohexyl)-4-fluoro-3-(trifluoromethyl)benzamide;

N-(cis-4-{[4-(dimethylamino)-6-methylquinazolin-2-yl]amino}cyclohexyl)-3,5-bis(trifluoromethyl)benzamide; and

N-(cis-4-{[4-(dimethylamino)-6-methylquinazolin-2-yl]amino}cyclohexyl)-3,4,5-trimethoxybenzamide;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

**38. (original):** The compound according to claim 1 selected from the group consisting of:

3-chloro-N-(cis-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}cyclohexyl)benzamide;

3,4-dichloro-N-(cis-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}cyclohexyl)benzamide;

N-(cis-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}cyclohexyl)-3,5-dimethoxybenzamide;

N-(cis-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}cyclohexyl)benzamide;

N-(cis-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}cyclohexyl)-4-methylbenzamide;

N-(cis-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}cyclohexyl)-4-fluorobenzamide;

N-(cis-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}cyclohexyl)-3-methoxybenzamide;

N-(cis-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}cyclohexyl)-3,4-difluorobenzamide; and

N-(cis-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}cyclohexyl)-3-(trifluoromethyl)benzamide;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

**39. (original):** The compound according to claim 34 wherein:

R<sub>1</sub> is selected from the group consisting of:

- (i) C<sub>1-8</sub> alkyl, and
- C<sub>1-8</sub> alkyl substituted by substituent(s) independently selected from the group consisting of:
- carbocyclic aryl,
  - carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
- halogen,
  - C<sub>1-5</sub> alkyl,
  - C<sub>1-5</sub> alkyl substituted by halogen,
  - C<sub>1-5</sub> alkoxy, and
  - C<sub>1-5</sub> alkoxy substituted by halogen,
- (ii) heterocyclyl, and
- heterocyclyl substituted by halogen,
- R<sub>2</sub> is -N(R<sub>2a</sub>)(R<sub>2b</sub>), wherein R<sub>2a</sub> and R<sub>2b</sub> are each independently C<sub>1-5</sub> alkyl;
- L is Formula (XIII);
- X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub> and X<sub>4</sub> are independently hydrogen or halogen; provided that at least one substituent selected from the group consisting of X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub> and X<sub>4</sub> is not hydrogen; and
- Y is -C(O)NR<sub>7</sub>- wherein R<sub>7</sub> is hydrogen or C<sub>1-5</sub> alkyl;
- wherein carbocyclic aryl is phenyl;
- heterocyclyl is pyridyl; and
- halogen is fluoro, chloro, bromo, or iodo;
- or a pharmaceutically acceptable salt, hydrate or solvate thereof.

**40. (original):** The compound according to claim 39 wherein  $R_2$  is  $-N(CH_3)_2$ ; L is Formula (XIII) wherein A and B are both a single bond;  $X_1$ ,  $X_2$ ,  $X_3$  and  $X_4$  are independently hydrogen or fluoro; provided that at least one substituent selected from the group consisting of  $X_1$ ,  $X_2$ ,  $X_3$  and  $X_4$  is not hydrogen; and Y is  $-C(O)NH-$ ;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

**41. (original):** The compound according to claim 1 selected from the group consisting of:

cis-N-benzyl-4- {[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}-cyclohexanecarboxamide;

cis-N-(3,5-dimethoxybenzyl)-4- {[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}cyclohexanecarboxamide;

cis-4- {[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}-N-(3-methoxybenzyl)cyclohexanecarboxamide;

cis-N-[(6-chloropyridin-3-yl)methyl]-4- {[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}cyclohexanecarboxamide;

cis-4- {[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}-N-[3-(trifluoromethyl)benzyl]cyclohexanecarboxamide;

cis-4- {[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}-N-[4-(trifluoromethyl)benzyl]cyclohexanecarboxamide;

cis-N-[3,5-bis(trifluoromethyl)benzyl]-4- {[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}cyclohexanecarboxamide;

cis-4- {[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}-N-(3-iodobenzyl)-cyclohexanecarboxamide; and

cis-N-[1-(4-bromophenyl)ethyl]-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}cyclohexanecarboxamide;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

**42. (original):** The compound according to claim 1 selected from the group consisting of:

cis-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}-N-(4-methylbenzyl)-cyclohexanecarboxamide;

cis-N-(3-chlorobenzyl)-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}-cyclohexanecarboxamide;

cis-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}-N-[(1R)-1-(3-methoxyphenyl)ethyl]cyclohexanecarboxamide;

cis-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}-N-(4-methoxybenzyl)cyclohexanecarboxamide;

cis-N-(2,4-dichlorobenzyl)-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}cyclohexanecarboxamide;

cis-N-(3,5-dichlorobenzyl)-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}cyclohexanecarboxamide;

cis-N-(4-bromobenzyl)-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}-cyclohexanecarboxamide;

cis-N-(2-bromobenzyl)-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}-cyclohexanecarboxamide;

cis-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}-N-[4-(trifluoromethoxy)benzyl]cyclohexanecarboxamide; and

cis-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}-N-[(1S)-1-(4-methylphenyl)ethyl]cyclohexanecarboxamide;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

**43. (original):** The compound according to claim 2 wherein Q is Formula (IIb).

**44. (original):** The compound according to claim 43 wherein:

R<sub>1</sub> is selected from the group consisting of:

C<sub>1-8</sub> alkyl, and

C<sub>1-8</sub> alkyl substituted by substituent(s) independently selected from the group consisting of:

- carbocyclic aryl,

- carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

- halogen,

- C<sub>1-5</sub> alkyl, and

- C<sub>1-5</sub> alkoxy,

R<sub>3</sub> is C<sub>1-5</sub> alkyl;

L is Formula (XIII); wherein R<sub>5</sub> and R<sub>6</sub> are both hydrogen; A and B are both a single bond;

Y is -C(O)NR<sub>7</sub>-;

wherein carbocyclic aryl is phenyl; and

halogen is fluoro, chloro, bromo, or iodo;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

**45. (original):** The compound according to claim 44 wherein R<sub>3</sub> is isopropyl;  
and Y is -C(O)NH-:

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

**46. (original):** The compound according to claim 1 is:  
cis-N-(3-chlorobenzyl)-4-[(4-isopropylquinazolin-2-  
yl)amino]cyclohexanecarboxamide;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

**47. (original):** The compound according to claim 1 wherein R<sub>1</sub> is selected  
from hydrogen, -CO<sub>2</sub>tBu, or -CO<sub>2</sub>Bn (Bn is a benzyl group);

R<sub>2</sub> is -N(R<sub>2a</sub>)(R<sub>2b</sub>), wherein R<sub>2a</sub> is hydrogen or C<sub>1-5</sub> alkyl; R<sub>2b</sub> is C<sub>1-5</sub> alkyl;

R<sub>3</sub> is C<sub>1-5</sub> alkyl;

R<sub>4</sub> is -N(R<sub>4a</sub>)(R<sub>4b</sub>) wherein R<sub>4a</sub> is hydrogen or C<sub>1-5</sub> alkyl; R<sub>4b</sub> is C<sub>1-5</sub> alkyl;

L is selected from Formula (V), (VIII), (IX), (XIII), (XVI), or (XVII);

X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub> and X<sub>4</sub> are independently selected from the group consisting of hydrogen,  
halogen, and C<sub>1-4</sub> alkyl; provided that at least one substituent selected from the group  
consisting of X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub> and X<sub>4</sub> is not hydrogen; and

Y is a single bond;

or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

**48. (currently amended):** A pharmaceutical composition comprising a  
therapeutically effective amount of a compound according to ~~any one of claims 1 to 47~~ claim  
1 in combination with a pharmaceutically acceptable carrier.

**49. (currently amended):** A method for the prophylaxis or treatment of  
improving memory function, sleeping and arousal, anxiety, depression, mood disorders,

seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction comprising administering to an individual suffering from said condition a therapeutically effective amount of a compound according to ~~any one of claims 1 to 47~~ claim 1 or a pharmaceutical composition according to claim 48.

**50. (currently amended):** A method for the prophylaxis or treatment of an eating disorder, obesity or an obesity related disorder comprising administering to an individual suffering from said condition a therapeutically effective amount of a compound according to ~~any one of claims 1 to 47~~ claim 1 or a pharmaceutical composition according to claim 48.

**51. (currently amended):** A method for the prophylaxis or treatment of anxiety, depression, schizophrenia, addiction, or epilepsy comprising administering to an individual suffering from said condition a therapeutically effective amount of a compound according to ~~any one of claims 1 to 47~~ claim 1 or a pharmaceutical composition according to claim 48.

**52. (currently amended):** A compound according to ~~any one of claims 1 to 47 or a pharmaceutical composition according to claim 48~~ claim 1 for use in a method of treatment of the human or animal body by therapy.

**53. (currently amended):** A compound according to ~~any one of claims 1 to 47 or a pharmaceutical composition according to claim 48~~ claim 1 for use in a method of



prophylaxis or treatment of an eating disorder, obesity or an obesity related disorder of the human or animal body by therapy.

**54. (currently amended):** A compound according to ~~any one of claims 1 to 47 or a pharmaceutical composition according to claim 48~~ claim 1 for use in a method of prophylaxis or treatment of anxiety, depression, schizophrenia, addiction, or epilepsy of the human or animal body by therapy.

**55. (currently amended):** A compound according to ~~any one of claims 1 to 47~~ claim 1 for the manufacture of a medicament for use in the prophylaxis or treatment of an eating disorder, obesity or obesity related disorders.

**56. (currently amended):** A compound according to ~~any one of claims 1 to 47~~ claim 1 for the manufacture of a medicament for use in the prophylaxis or treatment of anxiety, depression, schizophrenia, addiction, or epilepsy.

**57. (currently amended):** A method of producing a pharmaceutical composition comprising admixing a compound according to ~~any one of claims 1 to 47~~ claim 1 and a pharmaceutically acceptable carrier.